 
Official Title:  A RANDOMIZED, OPEN- LABEL, TWO -TREATMENT, TWO -
PERIOD, TWO -WAY CROSSOVER STUDY TO INVESTIGATE THE 
BIOEQUIVALENCE OF ENTRECTINIB POLYMORPH FORMS A 
AND C UNDER FASTED CONDITIONS IN HEALTHY SUBJECTS  
Study ID: [REMOVED] 
Document  Date : Protocol  Version 1: 05- Nov-2018 
 
 
 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November  2018 Page 1 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018  
A RANDOMIZED, OPEN- LABEL, TWO -TREATMENT, TWO -PERIOD, TWO -WAY 
CROSSOVER STUDY TO INVESTIGATE THE BIOEQUIVALENCE OF 
ENTRECTINIB POLYMORPH FORMS A AND C UNDER FASTED CONDITIONS IN 
HEALTHY  SUBJECTS  
 
    
Protocol GP41049 
 
Covance Study 8397015 
 
IND 120500 
  
for 
 
Genentech, Inc. 
1 DNA Way  
South San Francisco, California USA 94080-4990 
    
by 
 
Covance Early Clinical Segment 
3402 Kinsman Boulevard 
Madison, Wisconsin USA 53704 
 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November  2018 Page 2 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 STUDY IDENTIFICATION 
Sponsor Genentech, Inc. 
 1 DNA Way  
 South San Francisco, California USA 94080-4990 
 
Sponsor’s Study Contact , PhD 
 Clinical Pharmacologist  
 Roche Innovation Centre, Welwyn 
 Hexagon Place, 6 Falcon Way, Welwyn Garden C ity 
 Hertfordshire, United Kingdom, AL7 1TW 
 Sponsor’s Medical Monitor   
  
 Roche Innovation Centre, Basel, Grenzacherstrasse 124  
 Basel 4070, Switzerland  
 Study Site Covance Clinical Research Unit  
 1341 West Mockingbird Lane, Suite 200E 
 Dallas, Texas USA 75247 
 Principal Investigator  , MD, CPI  
 Covance Clinical Research Unit  
  
 Study Institutional Review Board   
 
 USA  
 Main Clinical L aboratory (Obtain information from Form FDA 1572) 
 Bioanalytical Laboratory   
  
  USA  
 

Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November  2018 Page 3 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 Protocol Biostatistician  , MSc  
 Covance Patient Solutions, Safety, and Data Sciences  
  
 
Protocol Pharmacokineticist   
 Covance Clinical Pharmacology Services – Medical & Scientific 
Affairs  
  
 Protocol Medical Writer  , PhD 
 Covance Patient Solutions, Safety, and Data Sciences  
  

Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November  2018 Page 4 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 TABLE OF CONTENTS  
 
1 SYNOPSIS  ........................................................................................................................ 11  
2 INTRODUCTION  ............................................................................................................ 13  
2.1 BACKGROUND  .................................................................................................. 13  
2.1.1  PHARMACOLOGY  ........................................................................... 13  
2.1.2  TOXICOLOGY AND SAFETY PHARMACOLOGY  ...................... 13  
2.1.3  PHARMACOKINETICS  .................................................................... 14  
2.1.4  CLINICAL PROGRAM  ..................................................................... 15  
2.2 STUDY RATIONALE  ......................................................................................... 16  
2.3 DOSE RATIONALE  ............................................................................................ 16  
2.4 BENEFIT:RISK ASSESSMENT  ......................................................................... 16  
3 STUDY OBJECTIVES AND CORRESPONDING ENDPOINTS  ................................. 17  
3.1 PRIMARY OBJECTIVE  ...................................................................................... 17  
3.2 SECONDARY OBJECTIVE  ................................................................................ 17  
3.3 PRIMARY ENDPOINTS  ..................................................................................... 17  
3.4 SECONDARY ENDPOINTS  ............................................................................... 17  
4 STUDY DESIGN .............................................................................................................. 17  
4.1 DESCRIPTION OF THE STUDY  ....................................................................... 17  
4.2 RATIONALE FOR STUDY DESIGN ................................................................. 19  
4.3 RATIONALE FOR SUBJECT POPULATION  ................................................... 20  
4.4 RATIONALE FOR EXPLORATORY ASSESSMENTS  .................................... 20  
4.5 RATIONALE FOR PHARMACOKINETIC SAMPLING SCHEDULE  ............ 20  
5 SUBJECT SELECTION  ................................................................................................... 20  
5.1 SCREENING PROCEDURES  ............................................................................. 20  
5.2 CHECK- IN PROCEDURES  ................................................................................ 20  
5.3 INCLUSION CRITERIA ...................................................................................... 21  
5.4 EXCLUSION CRITERIA .................................................................................... 21  
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November  2018 Page 5 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 5.5 REMOVAL OF SUBJECTS FROM STUDY PARTICIPATION  ....................... 22  
6 ASSESSMENT OF SAFETY  ........................................................................................... 23  
7 STUDY PROCEDURES  .................................................................................................. 23  
7.1 SCHEDULE OF STUDY ACTIVITIES  .............................................................. 23  
7.2 STUDY TREATMENT  ........................................................................................ 26  
7.2.1  DRUG SUPPLIES AND ACCOUNTABILITY  ................................ 26  
7.2.2  DOSE PREPARATION AND ADMINISTRATION  ........................ 27  
7.3 REMOVAL OF STUDY BLIND  ......................................................................... 28  
7.4 CONTRACEPTION  ............................................................................................. 28  
7.5 DIET, FLUID, AND ACTIVITY CONTROL  ..................................................... 29  
7.6 CONCOMITANT MEDICATIONS  .................................................................... 30  
7.7 PHARMACOKINETIC BLOOD SAMPLE COLLECTION AND PROCESSING
............................................................................................................................... 31  
7.8 ANALYTICAL METHODOLOGY  ..................................................................... 31  
7.9 CLINICAL LABORATORY EVALUATIONS  .................................................. 31  
7.10  12-LEAD ELECTROCARDIOGRAMS  .............................................................. 32  
7.11  VITAL SIGNS  ...................................................................................................... 32  
7.12  HOW DO YOU FEEL? INQUIRY  ...................................................................... 32  
7.13  PHYSICAL EXAMINATIONS  ........................................................................... 33  
7.14  CLINIC DISCHARGE PROCEDURES  .............................................................. 33  
7.15  STUDY COMPLETION/EARLY TERMINATION PROCEDURES  ................ 33  
8 ADVERSE EXPERIENCES  ............................................................................................ 33  
8.1 SAFETY PARAMETERS AND DEFINITIONS  ................................................ 33  
8.1.1  ADVERSE EVENTS  .......................................................................... 33  
8.1.2  SERIOUS ADVERSE EVENTS (IMMEDIATELY REPORTABLE TO THE SPONSOR)  .......................................................................... 34
 
8.1.3  ADVERSE EVENTS OF SPECIAL INTEREST (IMMEDIATELY REPORTABLE TO THE SPONSOR)  ............................................... 35
 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November  2018 Page 6 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 8.2 METHODS AND TIMING FOR CAPTURING AND ASSESSING SAFETY 
PARAMETERS  .................................................................................................... 35  
8.2.1  ADVERSE EVENT REPORTING PERIOD  ..................................... 36  
8.2.2  ELICITING ADVERSE EVENT INFORMATION  .......................... 36  
8.2.3  ASSESSMENT OF SEVERITY OF ADVERSE EVENTS  ............... 37  
8.2.4  ASSESSMENT OF CAUSALITY OF ADVERSE EVENTS ........... 37  
8.3 PROCEDURES FOR RECORDING ADVERSE EVENTS  ................................ 38  
8.3.1  RECORDING ADVERSE EVENTS ON THE CASE REPORT FORM  ................................................................................................. 38
 
8.4 IMMEDIATE REPORTING REQUIREMENTS FROM INVESTIGATOR TO SPONSOR ............................................................................................................. 43
 
8.4.1  REPORTING REQUIREMENTS FOR FATAL OR LIFE-THREATENING SERIOUS ADVERSE EVENTS  ........................... 44
 
8.4.2  REPORTING REQUIREMENTS FOR ALL SERIOUS ADVERSE EVENTS  ............................................................................................. 44
 
8.4.3  REPORTING REQUIREMENTS FOR CAS ES OF ACCIDENTAL 
OVERDOSE OR MEDICATION ERROR  ........................................ 46  
8.4.4  FOLLOW -UP OF SUBJECTS AFTER ADVERSE EVENTS .......... 47  
8.5 ADVERSE EVENTS THAT OCCUR AFTER THE ADVERSE EVENT REPORTING PERIOD  ......................................................................................... 48
 
8.5.1  EXPEDITED REPORTING TO HEALTH AUTHORITIES, INVESTIGATORS, INSTITUTIONAL REVIEW BOARDS, AND ETHICS COMMITTEES .................................................................... 48
 
9 STATISTICAL ANALYSES  ........................................................................................... 49  
9.1 SAFETY AND TOLERABILITY ANALYSIS ................................................... 49  
9.2 PHARMACOKINETIC ANALYSIS  ................................................................... 49  
9.3 INTERIM ANALYSIS  ......................................................................................... 50  
9.4 STATISTICAL ANALYSIS OF PHARMACOKINETIC DATA  ....................... 50  
9.5 STATISTICAL ANALYSES OF SAFETY DATA  ............................................. 51  
9.6 SAMPLE SIZE ..................................................................................................... 51  
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November  2018 Page 7 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 9.7 QUALITY CONTROL AND QUALITY ASSURANCE  .................................... 51  
10 ADMINISTRATIVE ASPECTS  ...................................................................................... 52  
10.1  CHANGE IN PROTOCOL ................................................................................... 52  
10.2  INVESTIGATOR MEETING; SITE INITIATION ............................................. 52  
10.3  DISCLOSURE  ...................................................................................................... 52  
10.4  MONITORING (CLINICAL RESEARCH ASSOCIATE)  ................................. 52  
10.5  INSTITUTIONAL REVIEW BOARD ................................................................. 53  
10.6  INFORMED CONSENT  ...................................................................................... 53  
10.7  RECORDS  ............................................................................................................ 53  
10.7.1  ELECTRONIC CASE REPORT FORMS  ......................................... 54  
10.7.2  SOURCE DATA DOCUMENTATION ............................................. 54  
10.7.3  USE OF COMPUTERIZED SYSTEMS ............................................ 55  
10.7.4  STUDY MEDICATION ACCOUNTABILITY ................................. 55  
10.7.5  DISCLOSURE OF DATA .................................................................. 56  
10.7.6  RETENTION OF RECORDS ............................................................. 56  
10.8  REFERENCE TO DECLARATION OF HELSINKI/BASIC PRINCIPLES  ...... 57  
PRINCIPAL INVESTIGATOR AGREEMENT  .......................................................................... 58  
SPONSOR AGREEMENT  ........................................................................................................... 59  
REFERENCES ............................................................................................................................. 60  
APPENDIX A – CLINICAL LABORATORY EVALUATIONS  ............................................... 61  
APPENDIX B – APPROXIMATE MAXIMUM BLOOD VOLUME COLLECT ED ................ 62  
 
TABLE OF TABLES  
 
Table  7-1  Schedule of Activities ........................................................................................... 24  
Table  7-2  Pharmacokinetic Sampling Scheme (Periods 1 and 2) ......................................... 26  
Table  7-3  Clinical Laboratory and Safety Assessment Windows ......................................... 26  
Table  7-4  Study Drugs .......................................................................................................... 27  
Table  8-1  Adverse Event Severity Grading Scale for Events Not Specifically Listed in NCI CTCAE  ................................................................................................................. 37
 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November  2018 Page 8 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 Table  8-2  Causal Attribution Guidance ................................................................................. 38  
 
TABLE OF FIGURES  
 
Figure 1  Median Entrectinib Plasma Concentration versus Time Profile Following a  
Single 600-mg Dose to Healthy Volunteers Under Fed or Fasted Conditions ..... 14  
Figure 2  Overview of Study Design .................................................................................... 18  
 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November  2018 Page 9 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 ABBREVIATIONS  
AE adverse event  
AESI  adverse event of special interest  
ALT  alanine aminotransferase 
API active pharmaceutical ingredient  
AST  aspartate aminotransferase 
AUC 0-t area under the concentration- time curve from Hour 0 to the last measurable 
concentration  
AUC 0-∞ area under the concentration-time curve extrapolated to infinity 
BMI  body mass index 
CBC  complete blood count 
CFR  Code of Federal Regulations 
CI confidence inte rval 
CL/F  apparent systemic clearance 
Cmax maximum observed concentration  
CNS  central nervous system  
CSR  Clinical Study Report  
Ct last measurable concentration  
CV coefficient of variation  
CYP  cytochrome P450 
EC Ethics Committee  
ECG  electrocardiogram  
eCRF  e lectronic Case Report Form  
EDC  electronic data capture  
ET early termination  
FDA  Food and Drug Administration 
FSH follicle -stimulating hormone 
GCP  Good Clinical Practice  
GI gastrointestinal  
HDYF?  How do you feel? 
HIV human immunodeficiency virus 
IB Investigator’s Brochure 
ICF Informed Consent Form 
ICH International Conference on Harmonis ation/International Council for 
Harmonisation  
IMP investigational medicinal product 
IND Investigational New Drug 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November  2018 Page 10 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 IRB Institutional Review Board  
IUD intrauterine device 
λz apparent terminal elimination rate constant  
NCI CTCAE  National Cancer Institute Common Terminology Criteria for Adverse Events  
P-gp P-glycoprotein 
PK pharmacokinetic(s) 
QTc QT interval corrected for heart rate  
QTcF  QT interval corrected through use of Fridericia’s formula  
R Reference  
RBC  red blood cell 
SAE  serious adverse event  
SAP Statistical Analysis Plan  
SOP Standard Operating Procedures 
T Test 
t1/2 apparent terminal elimination half -life 
tmax time to maximum observed concentration 
UA urinalysis  
ULN  upper limit of normal 
US United States  
Vz/F apparent volume of distribution during the terminal elimination phase 
WBC  white blood cell  
 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November  2018 Page 11 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 1 SYNOPSIS  
Title of Study:  A Randomized, Open-Label, Two -Treatment, Two -Period, Two -Way Crossover Study to  
Investigate the Bioequivalence of Entrectinib Polymorph Forms A and C under Fasted 
Conditions in Healthy Subjects  
Objectives:  The primary objective of this study is:  
• To demonstrate bioequivalence between entrectinib polymorph Forms A and C 
under fasted conditions in healthy adult male and female subjects  
The secondary objective of this study is:  
• To explore the safety and tolerability of a single 200 -mg oral dose of entrectinib 
polymorph Forms A and C in healthy adult male and female subjects  
Methodology /Study 
Design:  This is a randomized, open -label, 2 -treatment, 2 -period, 2 -way crossover study to 
demonstrate bioequivalence between entrectinib polymorph Forms A and C administered under fasted conditions in healthy male and female subjects. Potential subj ects will be 
screened to assess their eligibility to enter the study within 27  days (Days - 28 to -2) prior 
to study entry. Dosing will be on Day 1 of each period. Replacement subjects may be enrolled, only if deemed necessary by the Sponsor. Samples will be collected for analysis 
at specified timepoints.  
Number and General 
Description of Subjects:  A total of 28 subjects will be enrolled in the study at a single clinical site to complete a 
minimum of 26 subjects.  
Diagnosis and Main 
Criteria for Inclusion:  Healthy males and females, between 18 and 60 years of age, inclusive, within body mass 
index range of 18.0 to 32.0 kg/m2, inclusive, weighing at least 50 kg at Screening who 
are in good health, as determined by no clinically significant findings from medic al 
history, 12- lead electrocardiogram (ECG), clinical laboratory evaluations, and vital 
signs.  
Test Product(s), Dose, 
and Mode of Administration:  Subjects will receive the following 2 treatments in a randomized sequence. Each 
treatment will be dosed as 1 × 200- mg capsule administered orally  with 240 mL of water 
after an overnight fast (minimum 8 hours):  
• Single 200 -mg oral dose of entrectinib F06 capsule formulation Form A 
(Reference formulation)  
• Single 200 -mg oral dose of entrectinib F06 capsule formulation Form C (Test 
formulation)  
Duration of Treatment:  Planned Enrollment/Screening Duration :  approximately 4 weeks . 
Length of Each Confinement :  Subjects will be confined at the study site from the time of 
Check -in (Day  -1) of each period until Clinic Discharge on Day 5. There will be at least 
a 14-day washout between doses in Periods 1 and 2. There will be a follow- up telephone 
call 12 to 14 days after the last dose of study drug (Period 2).  
Planned Study Conduct Duration :  approximately 8 weeks . 
Criteria for Evaluation :  
Safety  Safety and tolerability assessments will include recording of adverse events, clinical 
laboratory evaluations, vital sign measurements, physical examinations, and ECGs.  
Criteria for Evaluation :  
Pharmacokinetics  The following pharmacokinetic (PK) parameters will be derived from the plasma 
concentrations of entrectinib and M5 using the model independent approach:   maximum 
observed concentration (C max), time to maximum observed concentration (t max), area 
under the conce ntration -time curve from Hour  0 to the last measurable concentration 
(AUC 0-t), area under the concentration -time curve  extrapolated to infinity (AUC 0-∞), 
apparent terminal elimination rate constant ( λz), apparent terminal elimination half -life 
(t1/2), appa rent systemic clearance (entrectinib only, CL/F), and apparent volume of 
distribution during the terminal elimination phase (entrectinib only, V z/F). 
Statistical Methods:  Descriptive statistics (mean, median, minimum, maximum, standard deviation, geometri c 
mean, and geometric coefficient of variation) will be calculated for all PK parameters 
and PK concentration data.  
The primary parameters for bioequivalence testing will be C max and AUC 0-t of 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November  2018 Page 12 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 entrectinib. A linear mixed model will be applied to analyze th e log -transformed primary 
PK parameters. The model assumes fixed effects for treatment, period, and sequence, and 
a random effect for subject within sequence. Estimates of geometric mean ratios on the original scale, together with the corresponding 90% con fidence intervals (CIs) , will be 
derived for the comparisons between Test and Reference treatments. Bioequivalence will be concluded if the 90% CIs for the treatment ratios fall within the no -effect boundaries 
of 0.80 and 1.25.  
Descriptive statistics will be calculated on the safety parameters. No formal statistical 
analyses are planned.  
 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November  2018 Page 13 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 2 INTRODUCTION  
2.1 BACKGROUND  
Entrectinib ( RO7102122, formerly known as RXDX-101) is a potent and selective inhibitor of 
TRKA, TRKB, TRKC, ROS1, and ALK receptor tyrosine kinase. These kinases are 
overexpressed or dysregulated in a number of types of cancer with constitutive activity, making 
the growth of the cancer cells dependent on or “addicted” to the abnormal kinases.1,2 Therefore, 
these kinases represent  attractive targets for anticancer therapy.  
 Refer to the Investigator’s Brochure (IB)
3 for detailed background information on entrectinib and 
for details on nonclinical and clinical studies. 
2.1.1 PHARMACOLOGY 
Entrectinib selectively inhibits TRKA/B/C, ROS1, and ALK tyrosine kinases at low nanomolar 
concentrations in vitro and is highly potent in inhibiting proliferation of tumor cell lines dependent on the expression of these kinases. Treatment of mice bearing different xenograft 
(TRKA- or ALK-dependent) or allograph (ROS1-dependent) tumors with 60 mg/kg entrectinib twice daily showed potent growth inhibition of TRKA-dependent tumors and even complete regression of ROS1- and ALK-dependent tumors. 
2.1.2 TOXICOLOGY AND SAFETY PHARMACOLOGY 
In in vivo toxicology studies, adverse findings were observed in the skin, liver, central nervous 
system (CNS), and hemolymphopoietic system of both rats and dogs, while gastrointestinal (GI) 
toxicity was also observed in dogs. These ef fects were dose- and exposure- dependent, and 
exhibited reversibility. Central and peripheral neurologic events were common, consistent with penetration of entrectinib into the CNS and the role of TRK receptors in neuronal development and maintenance; signs included incoordination, decreased activity, staggering, abnormal gait, tremors, hypoactivity, and depression. In Good Laboratory Practices repeat -dose studies, no 
observed adverse effect levels were 7.5 mg/kg/day in rats and 15 mg/kg/day in dogs.  Entrec tinib inhibited human ether- à go-go- related gene tail current in vitro with a half -maximal 
inhibitory concentration of 0.6 μM as free drug (approximating to 120 μM after correction for plasma protein binding in humans). In in vivo preclinical studies, mode rate but reversible 
prolongation of the QT interval corrected for heart rate (QTc) was noted on electrocardiograms (ECGs ) at high doses in dogs. 
 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November  2018 Page 14 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 Entrectinib was not mutagenic or clastogenic in in vitro or in vivo genotoxicity studies. There 
was no evidenc e of adverse effects on reproductive organs in repeat -dose toxicology studies. In 
an embryo-fetal developmental study, oral administration of entrectinib to pregnant rats during organogenesis caused developmental abnormalities at dose levels that also caused maternal toxicity.  
 Entrectinib is not phototoxic based on results from an in vivo rat study. However, microscopic findings in rats of neutrophil infiltrates of corneal stroma and single cell necrosis of the corneal epithelium at high doses were conside red entrectinib -related.  
2.1.3 PHARMACOKINETICS  
Entrectinib is readily absorbed following oral administration with reasonable oral bioavailability (31% to 76% in preclinical species) and with peak concentrations typically occurring 
approximately 4 hours after dosing  (Figure 1) . Entrectinib exposure is dose proportional, with no 
significant dose- or time -dependency. The terminal half -life of entrectinib is approximately 20 to  
30 hours.  Food has no significant effect on oral bioavailability from clinical capsule formulations containing acidulant ( Figure 1) . 
 
Figure  1 Median Entrectinib Plasma Concentration versus Time Profile Following a 
 Single 600- mg Dose to Healthy Volunteers Under Fed or Fasted Conditions  
 
Source: Study RXDX -101-154 CSR Figure 14.3 . 

Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November  2018 Page 15 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018  
Entrectinib is highly protein bound (≥99%) and has a high apparent volume of distribution (approximately 600 L), indicating extensive distribution into body tissues. Data also  suggest that 
entrectinib crosses the blood/brain barrier.  
 Entrectinib is primarily cleared by metabolism, with the majority of a dose being recovered as metabolites in feces and very little elimination of parent drug or metabolites via the kidney. 
Based on in vitro incubations, cytochrome P450 (CYP) 3A4 is the primary enzyme responsible for the biotransformation of entrectinib, with lesser contributions from other CYP s and Phase II 
enzymes. The M5 metabolite (formed by demethylation) is a major circulating metabolite and is also pharmacologically active.  
 In in vitro drug-drug interaction studies entrectinib exhibited potential to inhibit and induce the activities of CYP3A. A study on the interaction with transporters in vitro revealed that entrectinib is a poor P-glycoprotein (P-gp) substrate and has the potential to inhibit the 
transporters P -gp (MDR1), breast cancer resistance protein, and MATE1. 
2.1.4 CLINICAL PROGRAM  
The clinical program to date includes 10 healthy volunteer and 5 patient studies:  approximately 300 healthy volunteers and approximately 400 pa tients have received one or more doses of 
entrectinib. In patients with NTRK, ROS1, or ALK fusion-positive locally advanced or metastatic extracranial solid tumors, antitumor activity has been broadly observed among TRK, ROS1, and ALK inhibitor- naïve patients treated with entrectinib, including patients with CNS 
involvement. Based upon particularly compelling clinical safety and efficacy data and an assessment of unmet medical need, entrectinib development has focused on 2 patient populations, NTRK fusion-positive solid tumors and ROS1 fusion-positive non- small cell lung 
cancer.  
 In the 4 main entrectinib studies  in oncology patients , the most common treatment -related 
adverse events (AEs) were dysgeusia (39%), fatigue (31%), dizziness (23%), constipation (22%), diarrhea (19%), nausea (19%), paresthesia (17%), weight increased (17%), blood creatinine increased (14%), myalgia (14%), vomiting (12%), peripheral edema (12%), anemia (11%), and arthralgia (10%). All AEs were reversible with dose modifications, and t here was no evidence of 
cumulative toxicity, clinically significant hepatic toxicity, or clinically significant QTc 
prolongation. In single-dose clinical pharmacology studies, entrectinib doses up to 800 mg have 
been administered to healthy volunteers without significant safety findings. 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November  2018 Page 16 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 2.2 STUDY RATIONALE  
Entrectinib can exist in 2 polymorphic forms (Forms A and C).  
 
 
 
 
 
 
 
 
 Therefore, the principal aim of this study is to compare the 
in vivo pharmacokinetic ( PK) performance of 2 capsule formulations containing either 
polymorph Form A or C,  
 
2.3 DOSE RATIONALE  
The recommended dose of entrectinib for cancer  patients is 600 mg  once dail y administered  as 
3 × 200- mg capsules, and so a single -capsule dose of 200 mg is used for the current study. Single 
doses of entrectinib up to 800 mg have been administered to healthy volunteers in previous 
clinical pharmacology studies without notable saf ety or tolerability findings. 
2.4 BENEFIT:RISK ASSESSMENT  
There will be no therapeutic benefit for the healthy subjects participating in the study.  The risks of participation are primarily those associated with adverse reactions to the study drug, although there may also be some discomfort from collection of blood samples and other study procedures. The tolerability profile of entrectinib from administration of single doses to healthy subjects has been characterized from previous clinical studies. There have been few AEs following entrectinib dosing in previous clinical studies in healthy volunteers and no specific safety concerns have been identified about the use of entrectinib in healthy volunteers. Of the 
potential risks identified in the IB, none require s pecific monitoring or risk mitigation 
procedures. Potential drug- drug interactions with other medications are addressed by restrictions 
on concomitant medication use. Potential risks to a developing fetus from entrectinib exposure in utero are addressed by  exclusion of pregnant females from the study and the requirement for all 
participants to use effective contraception throughout the study.  

Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November  2018 Page 17 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 Overall, no significant safety concerns have been identified about the use of 200 mg entrectinib 
in healthy subjects. All subjects will be resident in the study center and remain under medical 
supervision following each study drug administration and will undergo a standard battery of safety assessments. Hence, the risks to participants in this study are considered acceptable. 
3 STUDY OBJECTIVES  AND CORRESPONDING ENDPOINTS  
3.1 PRIMARY OBJECTIVE 
The primary objective of this study is : 
• To demonstrate bioequivalence between entrectinib polymorph Forms A and C under 
fasted conditions in healthy adult male and female subjects  
3.2 SECONDARY OBJECTIVE  
The secondary objective of this study is : 
• To explore the safety and tolerability of a single 200-mg oral dose of entrectinib 
polymorph Forms A and C in healthy adult male and female subjects  
3.3 PRIMARY ENDPOINTS  
The primary endpoints are: 
• The geometric mean ratio s and associated 9 0% confidence intervals (CIs) of entrectinib 
and M5 metabolite PK parameters area under the concentration- time curve from Hour  0 
to the last measureable concentration  (AUC
0-t) and maximum observed concentration 
(Cmax) 
3.4 SECONDARY ENDPOINTS  
The secondary endpoints are: 
• Incidence and severity of AEs and incidence of abnormalities in laboratory safety tests, 
12-lead ECGs, and vital sign measurements 
4 STUDY DESIGN 
4.1 DESCRIPTION OF THE STUDY  
This is a randomized, open -label, 2-treatment,  2-period, 2-way crossover study to demonstrate 
bioequivalence between entrectinib polymorph Forms A and C administered under fasted 
conditions in healthy male and female subjects. In each treatment period, subjects will receive a 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November  2018 Page 19 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 Subjects will be confined at the study site from the time of Check -in (Day -1) of each period 
until Clinic Discharge on Day 5 in each period. The site will attempt to contact all subjects w ho 
received at least 1 dose of entrectinib (including subjects who terminate the study early) 
approximately 12 to 14 days after the last study drug administration. A detailed list of 
assessments to be conducted in this study is included in Table  7-1. 
 In this study, physical examinations, 12- lead ECGs, vital signs, How do you f eel? (HDYF?) 
inquiries, and clinical laboratory evaluations ( Appendix A ) will be performed at specified times 
during the study (for specific timepoints and details on each study variable, refer to Section 7). 
After informed consent has been obtained but prior to initiation of study drug administration, 
only serious AEs ( SAEs ) caused by protocol- mandated interventions will be reported. After 
study drug administration on Day 1 of Period 1, all AEs, whether volunteered, elicited, or noted upon physical examination, will be recorded throughout the study (i.e., from Day 1 of Period 1 until Early Termination [ET] or until the follow- up telephone call ). A schedule of activities is 
presented in  Table  7-1. 
 The end of study is defin ed as the date of the last scheduled study procedure for the last 
participating subject.  
4.2 RATIONALE FOR STUDY DESIGN 
A crossover design will be used to reduce the residual variability as every subject acts as their own control. A single- dose, crossover desi gn is the standard design to compare PK. Subjects will 
be randomized to 1 of 2 treatment sequences to minimize assignment bias.  
 This study is an open- label investigation because the PK parameters are believed not to be 
subject to bias. The crossover design further minimizes the effect of inter -subject variability . 
Blood sampling up to 96 hours postdose will allow the PK parameters of entrectinib and 
metabolite M5 to be adequately characterized based on prior data. The 14-day washout between 
entrectinib doses is considered sufficient to prevent carryover effects of the treatments based on the entrectinib apparent terminal elimination half -life (t
1/2) of approximately 20 to 30 hours and 
M5 t 1/2 of approximately 40 hours. 
 Doses will be administered in the fasted state for formulation comparison without the 
confounding effect of food. 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November  2018 Page 20 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 4.3 RATIONALE FOR SUBJECT POPULATION 
Healthy adult male and female subjects were chosen for inclusion in this study because they are 
free of health  problems that could otherwise make them more susceptible to drug toxicity or 
confound the interpretation of the study results, are not routinely using concomitant medications that could interact with the study drug, and can provide a standard basis for co mparison 
(i.e., control) with less variability.  
4.4 RATIONALE FOR EXPLORATORY ASSESSMENTS  
Not applicable. 
4.5 RATIONALE FOR PHARMACOKINETIC SAMPLING SCHEDULE  
The PK sampling schedule has been selected on the basis of data from previous studies in which 
a single dose of entrectinib was administered to healthy volunteers. The frequent sampling schedule is designed to capture data at a sufficient number of timepoints to provide a detailed profile of the concentration-time curve, including C
max, time to maximum observed concentration 
(tmax), and t 1/2. 
5 SUBJECT SELECTION 
A total of 28 healthy volunteer male and female subjects who meet all the protocol inclusion criteria and none of the exclusion criteria will be enrolled into the study. 
5.1 SCREENING PROCEDURES  
Refer to Table  7-1 for procedures performed for all potential subjects at the Screening visit.  
5.2 CHECK -IN PROCEDURES  
Refer to Table  7-1 for procedures performed a t Check -in (Day  -1), when subjects will report to 
the study site.  
 
For subjects to continue their participation in the study, the drug and alcohol (as applicable) screen (and for females of childbearing potential, the pregnancy test) must be negative and the 
clinical laboratory evaluations must be within the normal laboratory range (unless deemed not clinically significant by the Investigator). In addition, continued compliance with concomitant 
medication and other restrictions will be verified.  
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November  2018 Page 21 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 5.3 INCLUSION CRITERIA 
Subjects who meet the following criteria may be included in the study: 
1. Males or females, between 18 and 60  years of age, inclusive , at Screening ; 
2. Within body mass index ( BMI ) range 18.0 to 32.0 kg/m2, inclusive, and weighing at least 
50 kg at Screening ; 
3. Healthy in the opinion of the Investigator. Healthy is defined by the absence of evidence 
of any activ e disease or clinically significant medical condition based on a detailed 
medical history, physical examination, vital signs, 12-lead ECG, and laboratory safety test results;  
4. Clinical laboratory evaluations (including chemistry panel [fasted at least 8  hours], 
complete blood count [ CBC ], and urinalysis [ UA]) within the reference range for the test 
laboratory, unless deemed not clinically significant by the Investigator. Congenital nonhemolytic hyperbilirubinemia (e.g., suspicion of Gilbert’s syndrome based on total and direct bilirubin) is acceptable. In case of borderline or questionable results, tests may 
be repeated to confirm eligibility ; 
5. Negative test for selected drugs of abuse at Screening (does not include alcohol) and at Check -in (Day -1) of Period 1 (does include alcohol; Appendix A ); 
6. Negative hepatitis panel ( hepatitis B surface antigen and hepatitis C virus antibody ) and 
negative human immunodeficiency virus (HIV) antibody screens ( Appendix A ); 
7. Females will not be pregnant or breastfeeding , and female s of childbearing potential will 
agree to use highly- effective contraception as detailed in Section  7.4; 
8. Females of childbearing potential  (Section  7.4) must agree to refrain from donating eggs 
during the treatment period and for 6 weeks after the final dose of study drug; 
9. Males will agree to use contraception as detailed in Section  7.4 and will refrain from 
sperm donation from Check- in (Day -1) of Period 1 and for 90 days after  the final  dose of 
study drug; 
10. Able to comprehend and willing to sign an Informed Consent Form (IC F) and to comply 
with the study protocol and study restrictions. 
5.4 EXCLUSION CRITERIA  
The following will exclude potential subjects from the study: 
1. History of GI surgery (e.g., gastric bypass) or other GI disorder (e.g. malabsorption 
syndrome) that might affect absorption of medicines from the GI tract (cholecystectomy 
will be allowed); 
2. Presence of a clinically significant disease, illness, medical condition, or disorder, or any 
other medical history determ ined by the Investigator to be clinically significant and 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November  2018 Page 22 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 relevant. Ongoing chronic disorders that are not considered clinically significant are 
permissible , provided  they are stable;  
3. Have a QT interval corrected through use of Fridericia’s formula (QTcF) >450 msec or 
concurrent use of medications that may prolong the QT interval. If the QTcF measurement is >450 msec, the ECG will be repeated 2  additional times and a triplicate 
average will be used to determine eligibility ; 
4. Confirmed (e.g., 2 consecutive measurements) systolic blood pressure >140 or <90 mmHg, diastolic blood pressure >90 or <50 mmHg, or pulse rate > 100 or <40 beats 
per minute; 
5. Clinically significant change in health status, as judged by the Investigator, or any major illness within 4 weeks p rior to Screening, or clinically significant acute infection or 
febrile illness within 14 days prior to Screening;  
6. Any other ongoing condition, disease, or laboratory test result that the Investigator 
considers would render the subject unsuitable for the study, place the subject at undue risk, interfere with the ability of the subject to participate in or complete the study, or 
confound interpretation of study data; 
7. Use of moderate or potent inhibitors or inducers of CYP3A enzyme or the transporter P-gp within 28 days prior to Screening and during the entire study duration, or use of other prohibited medications within 14 days prior to Screening and during the entire study duration (see Section 7.6);  
8. Participation in any other clinical study involving an investigational medicinal product (IMP) or device within 3 0 days or 5 half-lives (if known), whichever is longer, before 
Screening;  
9. History of alcoholism, drug abuse, or addiction within 1 year prior to Screening;  
10. History of clinically significant hypersensitivity or severe allergic reaction to entrectinib 
or related compounds;  
11. Poor peripheral venous access;  
12. Donation or loss of over 500 mL of blood or donation of plasma from 3 months prior to Screening  through Follow-up; 
13. Receipt of blood products within 2 months prior to Check- in (Day  -1) of Period 1. 
5.5 REMOVAL OF SUBJECTS FROM STUDY PARTICIPATION  
Subjects will be informed that they are fre e to withdraw from the study at any time and for any 
reason. The Investigator may remove a subject from the study if, in the Investigator’s opinion, it 
is not in the best interest of the subject to continue the study. Subjects may be discontinued due 
to the following:  change in compliance with inclusion/exclusion criterion that is clinically 
relevant and affects subject safety, occurrence of AEs, occurrence of pregnancy, intake of 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November  2018 Page 23 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 non-permitted concomitant medication that might affect subject safety or study 
assessments/objectives, etc. Notification of discontinuation will immediately be made to the 
Sponsor’s Study Monitor. In case of premature discontinuation of study participation, ef forts will 
be made to perform all final study day assessments (see Section  7.15). The date the subject is 
withdrawn from the study and the reason for discontinuation will be recorded on the subject’s electronic Case Report Form (eCRF ). All dropouts will be followed until resolution of all their 
AEs or until the unresolved AEs are judged by the Investigator to have stabilized or returned to baseline, as applicable.  For subjects who are discontinued by the Investigator or who voluntarily withdraw prematurely from the study, replacement subjects will be enrolled only if deemed necessary by the Sponsor. Except for replacements, the subjects will be assig ned a number by study site  staff. Assignment 
of numbers will be in ascending order and no numbers will be omitted. Subject numbers will be used on all study documentation. Replacement subjects will be assigned a subject number by adding 100 or 1000 to the number of the subject they are replacing (e.g., Subject No. 105 replaces Subject No. 005).  The entire study may be discontinued at the discretion of the Investigator, Sponsor, or Sponsor’s Medical Monitor based on the occurrence of the following: 
• AEs unknown to date with respect to their nature, severity, and duration 
• Increased frequency , and/or severity , and/or duration of known AEs 
• Medical or ethical reasons affecting the con tinued performance of the 
study 
• Difficulties  in the recruitment of subjects 
• Cancellation of drug development 
6 ASSESSMENT OF SAFETY  
Subjects will undergo safety monitoring during the study, including assessment of the nature, frequency, and severity of AEs throughout the study, and clinical laboratory safety testing and measurement of ECGs and vital signs at intervals . 
7 STUDY PROCEDURES  
7.1 SCHEDULE OF STUDY ACTIVITIES  
The schedule of a ctivities is presented in Table  7-1. The PK sampling scheme is presented in 
Table  7-2. The clinical laboratory and safety assessment windows are presented in Table  7-3.
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November 2018  Page 24 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 Table  7-1 Schedule of Activities  
 Screening  Periods 1 and 2  Follow -Upa 
Study 
Procedures  Days  -28 to -2 -1 1 2 3 4 5 
12 to 14 
days after 
last dose Time (hours) 
relative to 
dosing   Check -In Predose  0 0.5 1 2 3 4 5 6 8 12 24 36 48 72 96/ 
Discharge/  
ET 
Confined to the Study Site   ˂−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−˃   Ambulatory (outpatient) Study 
Site Visits X                   
Informed Consent X                   Demographics  X                   Previous Medication and 
Compliance with 
Inclusion/Exclusion Criteria  X X                  
Medical History  X Xb 
                 
Physical Examinationc  X                  Height, Weight, and BMI X                   Single 12- Lead Safety ECG  X  X    X    X       X  Vital Signsd X  X    X    X       X  Chemistry Panel, CBC, and UAe X X                X  Drug and Alcohol Screene X X                  Hepatitis B, C, and HIV Screene X                   FSHe X                   Pregnancy Testf X X                X  AE Monitoring (HDYF? Inquiry)g 
   ˂−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−˃ 
Concomitant Medication 
Monitoring    ˂−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−˃  
Randomization (Period 1)    X                 
Study Drug Administrationh 
   X                Blood Sampling for Entrectinib 
and M5 PKi   X  X X X X X X X X X X X X X X  
AE = adverse event; BMI = body mass index; CBC = complete blood count (hematology); ECG = electrocardiogram; ET = Early Termination; 
FSH = follicle -stimulating hormone; HDYF? = how  do you feel?; HIV = human immunodeficiency virus; PK  = pharmacokinetic; UA = urinalysis . 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November 2018  Page 25 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 a Telephone call.  
b Interim medical history only , only includes any medical history that occurred between the end of the Screening visit and the Check -in visit . 
c A routine  physical examination on Day -1 of Period 1 and an abbreviated physical examination on Day -1 of Period 2  (Section 7.13). Symptom -drive n physical 
examinations may be performed at other times at the Investigator’s discretion.  
d Vital signs include :  oral temp erature, respiratory rate, and supine blood pressure and pulse  rate. 
e Refer to Appendix A  for details and a list of evaluations. Includes alcohol testing at Check -in (Day -1) only.  The FSH test is for postmenopausal females only.  
f Females  of childbearing potential only.  
g Adverse  event checks with interspersed HDYF? inquiries . Adverse event s are collected after administration of study drug.  
h There will be at least a 14-day washout between doses in Periods 1 and 2 . 
i For PK blood samples collected during the study, also refer to Table  7-2. 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November 2018  Page 26 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 Table  7-2 Pharmacokinetic Sampling Scheme  (Period s 1 and 2 ) 
Study 
Day Pharmacokinetic Sampling Timepoints  
(Hours)  Window (+/ -) Analytes (Matrix)  
Day 1 Predose  Any convenient 
time prior to dosing  Entrectinib  and M5 (plasma)  
0.5 3 minutes  Entrectinib and M5 (plasma)  
1 5 minutes  Entrectinib and M5 (plasma)  
2 10 minutes  Entrectinib and M5 (plasma)  
3 10 minutes  Entrectinib and M5 (plasma)  
4 10 minutes  Entrectinib and M5 (plasma)  
5 10 minutes  Entrectinib and M5 (plasma)  
6 10 minutes  Entrectinib and M5 (plasma)  
8 10 minutes  Entrectinib and M5 (plasma)  
12 10 minutes  Entrectinib and M5 (plasma)  
Day 2 24 10 minutes  Entrectinib and M5 (plasma)  
36 30 minutes  Entrectinib and M5 (plasma)  
Day 3  48 30 minutes  Entrectinib and M5 (plasma)  
Day 4  72 30 minutes  Entrectinib and M5 (plasma)  
Day 5  96 30 minutes  Entrectinib and M5 (plasma)  
 
Table  7-3 Clinical Laboratory and Safety Assessment Windows  
Safety Assessment  Timepointsa Window (+/ -) 
Predose 45 minutes  
0 to 8 hours post dose 15 minutes  
12 to 36 hours postdose  1 hour 
Days 3 to 5  4 hours  
a Safety assessments may include vital signs, electrocardiograms , physical examinations, and clinical laboratory 
assessments. Not all safety assessments will be performed at each timepoint specified.  
7.2 STUDY TREATMENT  
The IMP for this study is entrectinib.  
7.2.1 DRUG SUPPLIES AND ACCOUNTABILITY 
The Sponsor or designee will provide the Investigator with adequate quantities of the study drugs 
(see Table  7-4).  
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November 2018  Page 27 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 Table 7-4 Study Drug s 
Study Drug  Entrectinib  Entrectinib  
Formulationa Capsule F06 (Form A, Reference formulation)  Capsule F06 (Form C, Test formulation)  
Strength  200 mg  200 mg  
Supplier  Genentech  Genentech  
Manufacturer  Genentech  Genentech  
a Specific ingredients/purity will be identified on the Certificate of Analysis (or equivalent) that is supplied with the 
study drug(s).  
 
The lot numbers for the study drugs will be provided to the study site by the supplier/manufacturer as soon as available.  
 
Study drugs will be stored at controlled  room temperature (not above 25° C) under secure 
conditions. The study drugs will be transferred from the bulk supplies into the subject’s dose 
container by qualified study site  employees. Each unit dose container will be appropriately 
labeled.  
 The Investigator or designee will maintain an accurate record of the receipt of the test materials 
as shipped by the Sponsor or designee, including the date received. One copy of thi s receipt will 
be returned to the Sponsor when the contents of the test material shipment have been verified. In addition, an accurate drug disposition record will be kept, specifying the amount dispensed to each subject and the date of dispensation. This drug accountability record will be available for inspection at any time. At the completion of the study, the original drug accountability record 
will be available for review by the Sponsor upon request. 
 If deemed appropriate by the Sponsor, sufficient sam ples will be randomly selected from the 
supply provided by the Sponsor or designee and retained by the s tudy site to meet the retention 
requirements described in the United States (US) Title 21 Code of Federal Regulations  (CFR) 
320.38 and 320.63.  At the completion of the study, all unused drug supplies (except for retention supplies, if 
appropriate) will be returned to the Sponsor or designee or disposed of by the study site, per the Sponsor’s or designee’s written instructions. 
7.2.2 DOSE PREPARATION AND ADMINISTRATION 
Each unit dose will be prepared by qualified clinical staff based on the study randomization that 
will be provided by a Covance Biostatistician.  
 The assigned treatment will be administered on Day 1 of each period: 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November 2018  Page 28 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018  
Treatment A : Entrectinib F06 capsule formulation Form A ( Reference formulation) 
Treatment C : Entrectinib F06 capsule formulation Form C ( Test formulation) 
 
Each dose will be administered orally with approximately 240  mL of room temperature water 
after an overnight fast (minimum 8 hours). A hand and mouth check will be performed to verify that the dose administered was swallowed. Subjects will be instructed not to crush, split, or chew the entrectinib capsules. Subjects will continue to fast for at least 4 hours following entrectinib dosing.  Water (except water provided with entrectinib dosing) will be restricted 1 hour prior to and 1 hour after each entrectinib administration, but will be allowed ad libitum at all other times.  
 Doses of entrectinib will be separated by a washout period  of at least 14 days.  
 Appropriate unit doses, as described above, will be administered to consecutively numbered subjects. Although the timing of events requires that each subject will be consistently administered the appropriate dose at specific times, the exact dose time of consecutive subjects may be staggered to obviate the need to have all subjects on precisely the same study schedule. For each dose, the subject’s actual time will be recorded in the source documents and transcribed into the eCRFs.  
7.3 REMOVAL OF STUDY BLIND  
Not applicable; this is an open-label study and will not be blinded. 
7.4 CONTRACEPTION  
Postmenopausal is defined as at least 12 months without a period (i.e., amenorrhea) in a female 
at least 45 years of age and documented by a serum follic le-stimulating hormone [FSH] level 
consistent with postmenopausal status (i.e., ≥40 IU/L) in the absence of a reversible medical iatrogenic cause. Surgically sterile is defined as permanently sterile via hysterectomy, bilateral oophorectomy, and/or bilateral salpingectomy by reported medical history and/or medical 
records for at least 90 days prior to Screening.  Females who are not postmenopausal or surgically sterile are of childbearing potential and must agree to use one of the following examples of highly -effective contraception (failure rate of <1% 
per year) from the time of signing the informed consent or 10 days prior to Check-in (Day -1) of 
Period 1 and for 6 weeks after the final dose of study drug: 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November 2018  Page 29 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 • Bilateral tubal ligation  
• Bilateral tubal occlusion  (Essure)  
• Vasectomized male partner  
• Hormonal contraceptives that inhibit ovulation 
• Hormone- releasing intrauterine device (IUD) 
• Copper IUD 
 
Male subjects will either be surgically sterile with documented azoospermia (confirmed by 
reported medical history and/or medical records) for at least 90 days prior to Screening, or will be required to use the following approved method of contraception from Check- in (Day  -1) of 
Period 1 and for 90 days after  the final dose of study drug: 
• Male condom with spermicide 
 For subjects who are exclusively in same- sex relationships or are abstinent (when this is in line 
with the preferred and usual lifestyle of the subject), contraceptive requirements do not ap ply. If 
a subject who is in a same-sex relationship or abstinent at the time of signing the ICF becomes engaged in a heterosexual relationship, they must agree to use contraception, as described previously.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. If a male subject cannot provide proof of sterilization by medical records, the subject must agree to either true abstinence or a method of birth control, as outlined above.  Male subjects (including men who have had vasectomies) whose partners are currently pregnant should use a barrier method with spermicide for the duration of the study through Follow-up. 
This is to ensure that the fetus is not exposed to t he drug in the ejaculate.  
7.5 DIET, FLUID, AND ACTIVITY CONTROL  
Subjects will refrain from use of tobacco - or nicotine -containing products (including, but not 
limited to, cigarettes, e-cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine 
lozenges, and nicotine gum) within 6  months prior to Check- in (Day -1) of Period 1 and during 
the entire study.  Subjects will abstain from consuming alcohol- or caffeine -containing foods and beverages for 
72 hours prior to Check-in (Day -1) of Period 1 and during the entire study, unless deemed 
acceptable by the Investigator.  
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November 2018  Page 30 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018  
Subjects will abstain from consuming grapefruit- or Seville orange-containing foods and beverages for 7 days prior to Check-in (Day -1) of Period 1 and during the entire study, unless deemed acceptable by the Investigator.  
 Subjects will refrain from strenuous exercise from 48 hours prior to Check- in (Day -1) of 
Period  1 and during the period of confinement at the study site and will otherwise maintain their 
normal level of physical activ ity throughout the entire study (i.e., will no t begin a new exercise 
program or participate in any unusually strenuous physical exertion).  With the exception of dosing, as applicable, while confined at the study site, subjects will receive a standardized diet at scheduled times that do not conflict with other study- related activities.  
 See Section 7.2.2 for diet and fluid restrictions in regards to dose administration. 
 Subjects will remain ambulatory  or seated upright for 4 hours following entrectinib  
administration , except as necessitated by the occurrence of an AE(s) and/or study procedures. 
7.6 CONCOMITANT MEDICATIONS  
Subjects should not take any prescription or over -the- counter medication , vitamins, or minerals 
from 14 days prior to Screening and during the study, unless the Investigator has given prior consent. The following categories of medication are specifically prohibited from 28  days prior to 
Screening and during the study: 
• Moderate or potent inhibitors or inducers of CYP3A enzyme or P-gp transporter 
• Gastric pH -modifying agents such as proton pump inhibitors, H
2 receptor antagonists, 
and antacids 
• Psychoactive drugs or other drugs used for mental disorders. Examples include anti-depressants, anti -psychotics, sedatives, and stimulants 
 Acetaminophen (paracetamol) up to 2 g per day, medications to treat AEs, hormonal contraceptives, and hormone replacement therapy are allowed throughout the study. Ondansetron is permitted as a treatment for nausea for individual subjects at the discretion of the Investigator. 
Other medications for chronic, non-clinically significant conditions (e.g., thyroid hormone replacement medication) may be permitted providing the subject has been on a stable dose and dosing regimen for at least 3 months prior to Screening.  
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November 2018  Page 31 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 The administration of any other concomitant medications during the study is prohibited without 
prior approval of the Investigator, unless its use is deemed necessary in  a medical emergency. 
Any medication taken by a subject during the course of the study, including the name, strength, frequency of dosing, and reason for its use, will be documented in the source documents and the eCRF.  
7.7 PHARMACOKINETIC BLOOD SAMPLE COLLECT ION AND PROCESSING  
Blood samples for PK analysis of entrectinib and M5 levels will be collected via an indwelling 
catheter and/or via direct venipuncture using Vacutainer
 or equivalent evacuated collection 
tubes. Blood samples will be collected at the timepoints listed in Table  7-2. 
 
Processing, storage, and shipping instructions for these PK blood samples are presented in a separate laboratory manual.  
 After the plasma samples collected in the study are analyzed for en trectinib and M5 
concentrations, any residual samples may be used for analysis such as metabolite profiling and 
identification, interacting drug concentration measurements, ex vivo protein binding, or development of PK or pharmacodynamic assays.  Residual P K samples will be destroyed no later 
than 5 years after the final Clinical Study Report (CSR) has been completed . When a subject 
withdraws from the study, samples collected prior to the date of withdrawal may still be analyzed, unless the subject specifically requests in writing that the samples be destroyed or local 
laws require destruction of the samples. However, if samples have been tested prior to withdrawal, results from those tests will remain as part of the overall research data.  Sample 
retention ma y be detailed in the laboratory manual. 
7.8 ANALYTICAL METHODOLOGY 
Plasma concentrations of entrectinib and M5 will be determined  using a validated liquid 
chromatography tandem mass spectrometry bioanalytical procedure by an external vendor. 
7.9 CLINICAL LABORATORY EVALUATIONS  
Clinical laboratory evaluations (including chemistry panel [fasted at least 8 hours], CBC, and 
UA) will be collected at the timepoints listed in Table  7-1. 
 Screens for a hepatitis panel  and HIV antibody will be performed at Screening. A drug screen for 
selected drugs of abuse (not including alcohol) will be performed at Screening and repeated (but including an alcohol breath test) at Check -in (Day -1). A serum qualitative pregnancy test 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November 2018  Page 32 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 (females of childbearing potential only) and FSH test (postmenopausal females only) will be 
performed at the timepoints specified in Table  7-1. 
7.10 12-LEAD ELECTROCARDIOGRAMS  
A single  12-lead ECG will be obtained at the timepoints specified in Table  7-1. 
 
To minimize variability in autonomic tone and heart rate, subjects will rest quietly and in a supine position for at least 5 minutes prior to recording the ECG. Blood draws, other procedures, activity, and environmental distractions (e.g., television, radio, conversation) should be avoided 
during the pre-ECG resting period and between ECG recordings to minimize variability due to the effects of activity and stress on cardiac electrophysiology. Whenever possible, ECG tracings for each subject should be obtained from the same type of machine throughout the study. 
 When 12- lead ECGs are scheduled at the same time as blood draws, the blood draws will be 
obtained at the scheduled timepoint, and the 12- lead ECGs will be obtained as close as possible 
to the scheduled blood draw, but prior to the blood draw. 
7.11 VITAL SIGNS  
Vital signs (including oral temp erature, respiratory rate, and supine blood pressure and pulse 
rate) will be obtained at the timepoints specified in Table  7-1. 
 
Supine blood pressure and pulse rate will be obtained after the subject has been supine for at 
least 5  minutes. When vital signs are scheduled at the same time as blood draws, the blood draws 
will be obtained at the scheduled timepoint and the vital  sign s will be obtained as close as 
possible to the scheduled blood draw, but prior to the blood draw. 
7.12 HOW DO YOU FEEL? INQUIRY 
Subjects will be asked a non -leading H DYF? question such as “Have there been any changes in 
your health status since Screening/since you were last asked?” at the timepoints specified in 
Table  7-1. Subjects will also be encouraged to voluntarily report AEs occurring at any other time 
during the study. See Section 8.3 and Section 8.4  for reporting requirements for AEs and SAEs, 
respectively.  
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November 2018  Page 33 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 7.13 PHYSICAL EXAMINATIONS  
A routine or abbreviated physical examination will be performed at the timepoints specified in 
Table  7-1. Symptom -driven physical examinations may be performed at other times at the 
Investigator’s discretion.  
 
A routine physical examination will consist of an assessment of general appearance; skin ; 
thorax/lungs; abdomen; lymph nodes; head, ears, eyes, nose, throat, and neck (including thyroid) ; and cardiovascular,  musculoskeletal, and neurological systems. An abbreviated 
physical examination will consist of an assessment of general appearance, skin, thorax/lungs, cardiovascular  system , and abdomen. 
7.14 CLINIC DISCHARGE PROCEDURES  
Refer to Table  7-1 for procedures performed on the day of discharge. 
7.15 STUDY COMPLETION/EARLY TERMINATION PROCEDURES  
Refer to Table  7-1 for  procedures performed at  Follow-up or ET. 
8 ADVERSE EXPERIENCES  
8.1 SAFETY PARAMETERS AND DEFINITIONS  
Safety assessments will consist of monitor ing and recording AEs, including SAE s and AEs of 
special interest  (AESIs) , performing protocol- specified  safety laboratory assessments,  measuring 
protocol-specified vital signs, and conducting other protocol -specified tests that are deemed 
critical to the safety evaluation  of the study. The Sponsor or its designee is responsible for 
reporting relevant SAEs to the competent authority, other applicable regulatory authorities, and participating Investigators, in accordance with the International Conference on 
Harmonisation /International Council for Harmonisation (ICH) guidelines, Food and Drug 
Administration (FDA) regulations, European Clini cal Trials Directive (Directive  2001/20/EC), 
and/or local regulatory requirements.  
 Certain types of events require immediate reporting to the Sponsor, as outlined in Section  8.4. 
8.1.1 ADVERSE EVENTS 
According to the ICH Guideline for Good Clinical Practice ( GCP ), an AE is any untoward 
medical occurrence in a clinical investigation subject administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any of the following: 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November 2018  Page 34 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 • Any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product 
• Any new disease or exacerbation of an existing disease (a worsening in the character, 
frequency, or severity  of a known condition) 
• Recurrence of an intermittent medical condition (e.g., he adache) not present at baseline 
• Any deterioration in a laboratory value or other clinical test (e.g., ECG, X- ray) that is 
associated with symptoms or leads to a change in study  treatment or concomitant 
treatment or discontinuation from study drug 
• Adverse events that are related to a protocol -mandated intervention, including those that 
occur prior to assignment of study treatment (e.g., screening invasi ve procedures such as 
biops ies) 
8.1.2 SERIOUS ADVERSE EVENTS (IMMEDIATELY REPORTABLE TO THE 
SPONSOR)  
An SAE is any AE that meets any of the following criteria : 
• Is fatal ( i.e., the AE actually causes or leads to de ath) 
• Is life-threatening (i.e., t he AE , in the view of the Investigator, places the subject at 
immediate risk of death) ; this does not include any AE  that had it occurred in a more 
severe form or was allowed to continue might have caused death  
• Requires or prolongs inpatient hospitalization  
• Results in persistent or significant disability /incapacity ( i.e., the AE results in substantial 
disruption of the subject’s ability to conduct normal life functions) 
• Is a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to study drug 
• Is a significant  medical event in the Investigator ’s judgment (e.g., may jeopardize the 
subject or may require medical/surgical intervention to prevent one of the outcomes listed 
above) 
 All AEs that do not meet any of the criteria for serious should be regarded as non- serious AEs.  
 
The terms “severe” and “serious” are not synonymous. Severity refers to the intensity of an AE 
(e.g., rated as mild, moderate, or severe, according to National Cancer Institute Common 
Terminology Criteria for Adverse Events  [NCI CTCAE] ); the event itself may be of relatively 
minor medical significance (such as severe headache)  without any further findings. An event 
should be considered “serious” only if it meets the regulatory criteria outlined in the 
above-mentioned paragraph outlining seriousness criteria. 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November 2018  Page 35 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018  
Seriousness (not severity) serves as the guide for defining regulatory reporting obligations.  Severity , seriousness, and causality  need to be independently assessed for each  AE recorded on 
the eCRF . 
 Serious AEs are required to be reported by the Investigator to the Sponsor via the Covance 
Project Manager immediately (i.e., no more than 24 hours after learning of the event; see 
Section  8.4.2 for reporting instructions).  
8.1.3 ADVERSE EVENTS OF SPECIAL INTEREST (IMMEDIATELY REPORTABLE TO THE SPONSOR)  
Adverse events of special interest are required to be reported by the Investigator to the Sponsor via the Covance Project Manager immediately (i.e., no more than 24 hours after learning of the 
event; see Section  8.4.2 for reporting ins tructions). Adverse events of special interest for this 
study are as follows: 
• Cases of potential drug-induced liver injury that include an elevated alanine 
aminotransferase (ALT) or aspartate aminotransferase (AST) in combination with either 
an elevated bi lirubin or clinical jaundice, as defined by Hy’s Law (see Section  8.3.1.6); 
• Suspected transmission of an infectious agent by the study drug as defined below: 
o Any organism, virus, or infectious particle (e.g., prion protein transmitting transmissible spongiform encephalopathy), pathogenic or non-pathogenic, is 
considered an infectious agent. A transmission of an infectious agent may be 
suspected from clinical symptoms or laboratory findings that indicate an infection in a subject exposed to a medicinal product. The term applies only when a 
contamination of the study drug is suspected. 
• All grades syncope events  
• Grade ≥2 congestive cardiac failure  
• Grade ≥2 QT prolongation 
• Grade ≥3 cognitive disturbances (including confusion, mental status changes, hallucinations, or memory loss)  
8.2 METHODS AND TIMING FOR CAPTURING AND ASSESSING SAFETY PARAMETERS  
The Investigator is responsible for ensuring that all AEs (as defined in Section  8.1) are recorded 
on the AE eCRF and reported to the Sponsor  via the Covance Project Manager in accordance 
with protocol instructions  (see Section 8.4.2). 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November 2018  Page 36 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018  
For each AE recorded on the AE eCRF, the Investigator will make an assessment of seriousness (see Section 8.1.2 for seriousness criteria), severity, and causality (see Section s 8.2.3 and 8.2.4).  
8.2.1 ADVERSE EVENT REPORTING PERIOD  
Investigators will seek information on AEs at each subject contact. All AEs, whether reported by the subject or noted by study personnel, will be recorded in the subject’s medical record and on the AE eCRF.  
 After informed consent has been obtained but prior to initiation of study drug administration, only SAEs caused by a protocol- mandated intervention (e.g., discontinuation of medications) 
will be reported (see Section 8.4.2 for instructions for reporting SAEs). After initiation of study 
drug administration, all AEs  will be re ported until 28 days after the final dose. 
 Instructions for reporting AEs that occur after the AE reporting period are provided in Section  8.5. 
 The Investigator is not required to actively monitor subjects after the study has ended or for AEs after the end of the AE reporting period (defined as 28 days after the final dose of study drug). 
However, the Sponsor should be notified if the Investigator becomes aware of any death, other SAEs, or AESI s occurring after the end of the AE reporting period that are believed to be related 
to prior study drug treatment . The Sponsor should also be notified if the Investigator becomes 
aware of the development of cancer or a congenital anomaly/birth defect in a subsequently conceived offspring of a female subject  exposed to study drug (or the female partner of a male 
subject exposed to study drug). 
8.2.2 ELICITING ADVERSE EVENT INFORMATION  
A consistent methodology of non-directive questioning should be adopted for eliciting AE 
information at all subject evaluation timepoints. Examples of non-directive questions include the following: 
• “How have you felt since your last clinic visit?” 
• “Have you had any new or changed health problems since you were last here?” 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November 2018  Page 37 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 8.2.3 ASSESSMENT OF SEVERITY OF ADVERSE EVENTS  
The AE severity grading scale for the NCI CTCAE (version 5.0) will be used  for assessing AE 
severity. Table  8-1 will be used  for assessing AE severity  for AEs that are not specifically listed 
in the NCI CTCAE . 
 
Table  8-1 Adverse Event Severity Grading Scale for Events Not Specifically Listed in 
NCI CTCAE 
Grade  Severity  
1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or 
intervention not indicated  
2 Moderate; minimal, local, or non -invasive intervention indicated; or limiting age -appropriate 
instrumental activities of daily livinga 
3 Severe or medically significant, but not immediately life -threatening; hospitalization or 
prolongation of  hospitalization indicated; disabling; or limiting  self-care activities of daily 
livingb,c 
4 Life-threatening consequences or urgent intervention indicatedd 
5 Death related to adverse eventd 
NCI CTCAE  = National Cancer Institute Common Terminology Criteria for Adverse Events.  
Note:  Based on the NCI CTCAE (v 5.0), which can be found at:  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc htm  
a Instrumental activities of daily living refer to preparing meals, shopping for groceries  or clothes, using the 
telephone, managing money, etc.  
b Examples of self -care activities of daily living include bathing, dressing and undressing, feeding oneself, using 
the toilet, and taking medications, as performed by subjects who are not bedridden.  
c If an event is assessed as a “significant medical event,” it must be reported as an SAE (see Section 8.4.2 for 
reporting instructions), per the definition of SAE in Section  8.1.2 . 
d Grade 4 and 5 events must be reported as SAEs (see Section 8.4 for reporting instructions), per the definition of 
SAE in Section 8.1.2 . 
8.2.4 ASSESSMENT OF CAUSALITY OF ADVERSE EVENTS  
Investigators should use their knowledge of the subject, the circumstances surrounding the event, 
and an evaluation of any potential alternative causes to determine whether an AE is considered to be related to the study drug, indicat ing “yes” or “no” accordingly. The following guidance 
should be taken into consideration (see also Table  8-2):  
• Temporal relationship of event onset to the initiation of study drug 
• Course of the event, with special consideration of the effects of dose reduction, 
discontinuation of study drug, or reintroduction of study drug (as applicable) 
• Known association of the event with the study drug or with similar treatments  
• Known association of the event with the disease under study 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November 2018  Page 38 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 • Presence of risk factors in the subject  or use of concomitant medications known to 
increase the occurrence of the event  
• Presence of non -treatment- related factors that are known to be associated with the 
occurrence o f the event 
Table  8-2 Causal Attribution Guidance  
Is the adverse event suspected to be caused by the study drug based on facts, evidence, science- based rationales, and 
clinical judgment?  
YES There is a plausible temporal relationship between the onset of the adverse event  and administration of the 
study drug, and the adverse event cannot be readily explained by the subject’s clinical state, intercurrent 
illness, or concomitant therapies; and/o r the adverse event  follows a known pattern of response to the 
study drug; and/or the adverse event abates or resolves upon discontinuation of the study drug  or dose 
reduction and, if  applicable, reappears upon re- challenge.  
Investigators should apply fact s, evidence, or rationales based on scientific principles and clinical 
judgment to support a causal/contributory association with a study drug . 
NO Adverse events will be considered related, unless they fulfill the criteria as specified below.  
Evidence exists that the adverse event has an etiology other than the study drug (e.g., pre-existing medical 
condition, underlying disease, intercurrent illness, or  concomitant medication); and/or the adverse event 
has no plausible temporal relationship to administration of the study drug  (e.g., cancer diagnosed 2 days 
after first  dose of study drug).  
Note :  The Investigator’s assessment of causality for individual adverse event  reports is part of the study 
documentation process. Regardless of the “Yes” or “No” causality assessment for individual adverse event 
reports, the Sponsor will promptly evaluate all reported serious adverse events  against cumulative product 
experience to identify and expeditiously communicate possible new safety findings to Investigators and 
applicable regulatory authorities. Attribution of serious adverse event s will be reviewed on an ongoing 
basis, and may be changed as additional clinical data emerges ( e.g., reversibility of adverse event , 
new clinical findings in subject  with adverse event , effects of re- treatment, and adverse  event s in 
other subject s). 
8.3 PROCEDURES FOR RECORDING ADVERSE EVENTS  
8.3.1 RECORDING ADVERSE EVENTS ON THE CASE REPORT FORM  
Investigators should use correct medical terminology/concepts when recording AEs on the AE 
eCRF . Colloquialisms and abbreviations should be avoided. 
 All AEs should be recorded on the AE eCRF page. If the AE qualifies as an SAE or non- serious 
AESI , the Investigator should record all case details that can be gathered immediately (i.e., 
within 24 hours after learning of the event) on a paper Clinical Trial SAE/AE SI Reporting Form. 
The completed paper Clinical Trial SAE/AE SI Reporting Form and s afety fax coversheet  should 
be emailed to Roche Safety Risk Management  via the Covance Project Manager within 24 hours 
of lear ning of the event (see Section 8.4.2).  The AE and SAE eCRF should also be completed  
within this timeframe. It is important that the information on the SAE Reporting F orm and AE 
and SAE eCRF is consistent and identical.  
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November 2018  Page 39 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018  
Only 1 AE term  should be recorded in the event field on the AE eCRF . 
8.3.1.1 DIAGNOSIS VERSUS SIGNS AND SYMPTOMS  
If known, a diagnosis should be recorded on the AE eCRF rather than individual signs and 
symptoms ( e.g., record only liver failure or hepatitis rather than jaundice, asterixis, and elevated 
transaminases). However, if a constellation of signs and/or symptoms cannot be medically characterized as a single diagnosis or syndrome at the time of reporting, each individual event should be recorded on the AE eCRF . If a diagnosis is subsequently established, all previously 
reported AEs based on signs and symptoms should be nullified and replaced by 1 AE report based on the single diagnosis, with a starting date that corresponds to the starting date of the first symptom of the eventual diagnosis. 
8.3.1.2 ADVERSE EVENTS THAT ARE SECONDARY TO OTHER EVENTS  
In general, AEs that are secondary to other events (e.g., cascade events or clinical sequelae) 
should be identified by their primary cause, with the exception of severe or serious secondary events. A medically significant secondary AE that is separated in time from the initiating event 
should be recorded as an independent event on the AE eCRF. For example: 
• If vomiting results in mild dehydration with no additional treatment in a healthy adult, 
only vomiting should be reported on the eCRF. 
• If vomiting results in severe dehydration, both events should be reported separately on 
the eCRF.  
• If a severe GI hemorrhage leads to renal failure, both events should be reported 
separately on the eCRF.  
• If dizziness leads to a fall and subsequent fracture, al l 3 events should be reported 
separately on the eCRF.  
• If neutropenia is accompanied by an infection, both events should be reported separately on the eCRF. 
 
All AEs should be recorded separately on the AE eCRF if it is unclear as to whether the events are associated . 
8.3.1.3 PERSISTENT OR RECURRENT ADVERSE EVENTS  
A persistent AE is one that extends continuously, without resolution between subject evaluation timepoints. Such events should only be recorded once in the AE eCRF. The initial severity 
(intensity or grade ) of the event will be recorded at the time the event is first reported. If a 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November 2018  Page 40 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 persistent AE becomes more severe, the most extreme severity should also be recorded on the 
AE eCRF. If the event becomes serious, it should be reported to the Sponsor immediately (i.e., no more than 24 hours after learning that the event became serious; see Section 8.4.2 for 
reporting instructions). The AE eCRF should be updated by changing the event from “non-serious” to “serious,” providing the date that the event became serious, and by completing all data fields related to SAEs.  
 A recurrent AE is one that resolves between subject evaluation timepoints and subsequently recurs. Each recurrence of an AE should be recorded as a separate event on the AE eCRF . 
8.3.1.4 ABNORMAL LABORATORY VALUES  
Not every laboratory abnormality qualifies as an AE. A laboratory test result should be reported as an AE if it meets any of the following criteria: 
• Is accompanied by clinical symptoms 
• Results in a change in study treatment (e.g., dosage modification, treatment interruption, or treatment discontinuation) 
• Results in a medical intervention (e.g., potassium supplementation for hypokalemia) or a 
change in concomitant therapy 
• Is clinically significant in the  Investigator’s judgment 
 
It is the Investigator’s responsibility to review all laboratory findings. Medical and scientific 
judgment should be exercised in deciding whether an isolated laboratory abnormality should be classified as an AE.  
 If a clinically significant laboratory abnormality is a sign of a disease or syndrome (e.g., alkaline phosphatase and bilirubin 5 times the upper limit of normal [ ULN ] associated with cholestasis ), 
only the diagnosis (i.e., cholestasis) should be recorded on the AE eCRF. 
 If a clinically significant laboratory abnormality is not a sign of a disease o r syndrome, the 
abnormality itself should be recorded on the AE eCRF, along with a descriptor indicating whether the test result is above or below the normal range (e.g., “ elevated potassium, ” as 
opposed to “abnormal potassium” ). If the laboratory abnormality can be characterized by a 
precise clinical term per standard definitions, the clinical term should be recorded as the AE. For example, an elevated serum potassium level of 7.0 mEq/L should be recorded as “hyperkalemia.”  
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November 2018  Page 41 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 Observations of the same clinically significant laboratory abnormality from visit to visit should 
only be recorded once on the AE eCRF (see Section 8.3.1.3 for details on recording persistent AEs) . 
8.3.1.5 ABNORMAL VITAL SIGN VALUES  
Not every vital sign abnormality qualifies as an AE. A vital sign result should be reported as an AE if it meets any of the following criteria:  
• Is accompanied by clinical symptoms 
• Results in a change in study treatment (e.g., dosage modification, treatment interruption, or treatment discontinuation) 
• Results in a medical intervention or a change in concomitant therapy 
• Is clini cally significant in the Investigator’s judgment 
 It is the Investigator’s responsibility to review all vital sign findings. Medical and scientific judgment should be exercised in deciding whether an isolated vital sign abnormality should be classified as an AE.  
 If a clinically significant vital sign abnormality is a sign of a disease or syndrome (e.g., high blood pressure), only the diagnosis (i.e., hypertension) should be recorded on the AE eCRF.  Observations of the same clinically significant vital sig n abnormality from visit to visit should 
only be recorded once on the AE eCRF (see Section 8.3.1.3 for details on recording persistent AEs) . 
8.3.1.6 ABNORMAL LIVER FUNCTION TESTS  
The finding of an elevated ALT or AST (>3 × ULN) in combination with either an elevated total bilirubin (>2 × ULN) or clinical jaundice in the absence of cholestasis or other causes of hyperbilirubinemia is considered to be an indica tor of severe liver injury  (as defined by Hy’s 
Law). Therefore, Investigators must report the occurrence of either of the following as an AE : 
• Treatment -emergent ALT or AST >3 × ULN in combination with total bilirubin >2 × 
ULN  
• Treatment -emergent ALT or AST >3 × ULN in com bination with clinical jaundice  
 The most appropriate diagnosis or (if a diagnosis cannot be established) the abnormal laboratory values should be recorded on the AE eCRF (see Section 8.3.1 ) and reported to the Sponsor 
immediately (i.e., no more than 24 hours after learning of the event), either as an SAE or an AESI  (see Section 8.4.2 ). 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November 2018  Page 42 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 8.3.1.7 DEATHS  
All deaths that occur during the protocol-specified AE reporting period (see Section  8.2.1), 
regardless of relationship to study drug, will be recorded on the  AE eCRF as well as on the paper 
Clinical Trial SAE Reporting F orm and immediately reported to the Sponsor via the Covance 
Project Manager (see Section 8.4.2 for reporting instructions) . 
 
Death should be considered an outcome and not a distinct event. The event or condition that caused or contributed to the fatal outcome should be recorded as the single medical concept on the AE eCRF. Generally, only 1 such event should be reported. If the cause of death is unknown and cannot be ascertained at the time of reporting, “unexplained death” should be recorded on the AE eCRF. If the cause of death later becomes available (e.g., after autopsy), “unexplained death” should be replaced by the establis hed cause of death . The term “sudden death” should not 
be used unless combined with the presumed cause of death (e.g., “sudden cardiac death”).  
 Deaths that occur after the AE reporting period should be reported as described in Section  8.5. 
8.3.1.8 PRE- EXISTING MEDICAL CONDITIONS  
A pre -existing medical condition is one that is present at the Screening visit for this  study. Such 
conditions should be recorded on the General Medical History  and Baseline Conditions eCRF 
page.  A pre -existing medical condition should be recorded as an AE only if the frequency, severity, or 
character of the condition worsens during the study. When recording such events on an AE eCRF, it is important to convey the concept that the pre-existing condition has changed by including applicable descriptors ( e.g., “ accelerated worsening of  headaches”).  
8.3.1.9 HOSPITALIZATION OR PROLONGED HOSPITALIZATION  
Any AE that results in hospitalization  (i.e., inpatient  admission to a hospital) or prolonged 
hospitalization should be documented and reported as an SAE (per the definition of SAE in Section 8.1.2) except as outlined below.  
 An event that leads to hospitalization under the following circumstances should not be reported 
as an AE or SAE : 
• Hospitalization for respite care  
• Hospitalization for a pre-existing condition, provided that all of the following criteria are 
met: 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November 2018  Page 43 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 o The hospitalization was planned prior to the study or was scheduled during the 
study when elective surgery became necessary because of the expected no rmal 
progression of the disease 
o The su bject has not experienced an AE 
 An event that leads to  hospitalization under the following circumstances is  not considered to be 
an SAE but should be reported as an AE instead:  
• Hospitalization that was necessary because of the subject’s requirement for outpatient 
care outside of normal outp atient clinic operation hours 
8.4 IMMEDIATE REPORTING REQUIREMENTS FROM INVESTIGATOR TO SPONSOR  
Certain events require immediate reporting to allow the Sponsor to take appropriate measures to address potential new risks in a clinical trial. The Investigator mu st report such events to the 
Sponsor immediately via the Covance Project Manager; under no circumstances should reporting take place more than 24 hours after the Investigator learns of the event. The following is a list of events that the Investigator must  report to the Sponsor within 24 hours (see Section 8.4.2) after 
learning of the event, regardless of relationship to study drug: 
• SAEs (s ee Section 8.4.2 for further details)  
• AESIs (see Section 8.1.3 for further details)  
• Pregnancies (see Section 8.4.2.3 for further details)  
• Accidental overdoses or medication errors (see Section 8.4.3 for details on reporting 
requirements)  
 The Investigator must report new significant follow -up information for these events to the 
Sponsor immediately via the Covance Project Manager (i.e., no more than 24 hours after becoming aware of the information). New significant information includes the following: 
• New signs or symptoms or a change in the diagnosis 
• Significant new diagnostic test results  
• Change in causality based on new information 
• Change in the event’s outcome, including recovery 
• Additional narrative information on the clinical course of the event  
 Investigators must also comply with local requirements for reporting SAEs to the local health authority and Institutional Review Board (IRB)/ Ethics Committee (EC ). 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November 2018  Page 44 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 8.4.1 REPORTING REQUIREMENTS FOR FATAL OR LIFE- THREATENING 
SERIOUS ADVERSE EVENTS  
Any life-threatening (e.g., imminent risk of death) or fatal AE that is attributed to study drug by 
the Investigator will be telephoned to the Medical Monitor immediately, followed by completion 
of the paper Clinical Trial SAE Reporting Form within 24 hours of learning of the event as 
described in  Section 8.4.2. 
 Medical Monitor :  
 F. Hoffmann- La Roche AG  
  (Office Telephone No.) 
  (Mobile Telephone No.) 
8.4.2 REPORTING REQUIREMENTS FOR ALL SERIOUS ADVERSE EVENTS  
8.4.2.1 EVENTS THAT OCCUR PRIOR TO STUDY DRUG INITIATION 
After informed consent has been obtained but prior to initiation of study drug, only SAEs caused by protocol- mandated intervention should be reported. The paper Clinical Trial SAE/AE SI 
Reporting Form provided to the Investigator should be completed and submitted to the Sponsor via the Covance Project Manager immediately (i.e., no more than 24 hours after learning of the event), either by faxing or by scanning and emailing the form using the fax number or email address provided below.  The Covance Project Ma nager to receive the Investigator -generated SAE reports: 
Name:  , RN, BSN, CCRC  
Email Address:   
 (Office Telephone No.)  (Mobile Telephone No.)  
8.4.2.2 EVENTS THAT OCCUR AFTER STUDY DRUG INITIATION  
After initiation of study drug, SAEs and AESIs  will be reported until 28 days after the final dose 
of study drug. Investigators should record all case details that can be gathered immediately on a paper Clinical Trial SAE/AESI  Reporting Form. The paper Clinical Trial SAE/AE SI Reporting 
Form should be completed and submitted to the Sponsor (via the Covance Project Manager) immediately (i.e., no more than 24 hours after learning of the event), either by faxing or by scanning and emailing the form using the fax number or email address provided in Section  8.4.2.1. All information will also need to be entered into the AE eCRF. 
 

Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November 2018  Page 45 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 Relevant follow-up information should be submitted to Roche Safety Risk Management via the 
Covance Project Manager on an updat ed paper Clinical Trial SAE/AE SI Reporting Form as soon 
as it becomes available and/or upon request. Any updates to the paper Clinical Trial SAE/AE SI 
Reporting Form must also be updated in electronic data capture ( EDC) on the AE eCRF.  
8.4.2.3 REPORTING REQUIREMENTS FOR PREGNANCIES  
8.4.2.3.1 PREGNANCIES IN FEMALE SUBJECTS  
Female subject s of childbearing potential will be instructed to immediately inform the 
Investigator if they become pregnant during the study or within 28 days after the final dose of 
study drug. A paper Clinical Trial Pregnancy Reporting F orm should be completed by the 
Investigator immediately (i.e., no more than 24 hours after learning of the pregnancy) and emailed to Roche Safety Risk Management via the Covance Project Manager  (see Section 8.4.2 
for reporting instructions). Pregnancy should not be recorded on the AE  eCRF. The Investigator 
should discontinue study drug and counsel the subject , discussing the risks of the pregnancy and 
the possible effects on the fetus. Monitoring of the subject should continue until conclusion of 
the pregnancy. Any SAEs associated with the pregnancy (e.g., an event in the fetus, an event in the mother during or after the pregnancy, or a congenital anomaly/birth defect in the child) should be reported on the AE eCRF. In addition, the Investigator will submit a paper Clinical Trial Pregnancy Reporting Form when updated information on the course and outcome of the pregnancy becomes available.  
8.4.2.3.2 PREGNANCIES IN FEMALE PARTNERS OF MALE SUBJECTS  
Male subjects will be instructed through the ICF to immediately inform the Investigator if their partner becomes pregnant during the study or within 28 days after the final dose of study drug. A 
paper Clinical Trial Pregnancy Reporting Form should be completed by the Investigator immediately (i.e., no more than 24 hours after learning of the pregnancy) and emailed to Roche Safety Risk Management via the Covance Project Manager (see Section 8.4.2 for reporting 
instructions). Attempts should be made to collect and report details of the course and outcome of any pregnancy in the partner of a male subject exposed to study drug. When perm itted by the 
site, t he pregnant partner would need to sign an Authorization for Use and Disclosure of 
Pregnancy Health Information to allow for follow-up on her pregnancy. If the authorization has 
been signed, the Investigator should submit a Clinical Tria l Pregnancy Reporting Form when 
updated information on the course and outcome of the pregnancy becomes available. An Investigator who is contacted by the male subject or his pregnant partner may provide 
information on the risks of the pregnancy and the possible effects on the fetus, to support an informed decision in cooperation with the treating physician and/or obstetrician. 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November 2018  Page 46 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 8.4.2.3.3 CONGENITAL ANOMALIES/BIRTH DEFECTS AND ABORTIONS  
Any congenital anomaly/birth defect in a child born to a female subject exposed to the study 
drug or the female partner of a male subject exposed to the study drug should be classified as an SAE, recorded on the AE eCRF , and reported to the Sponsor immediately via the Covance 
Project Manager ( i.e., no more than 24 hours after learning of the event; see Section 8.4.2).  Any 
abortion should be reported in the same fashion (as the Sponsor considers abortions to be medically significant  events).  
8.4.3 REPORTING REQUIREMENTS FOR CASES OF  ACCIDENTAL OVERDOSE 
OR MEDICATION ERROR  
Accidental overdose and medication error (hereafter collectively referred to as “special situations”), are defined as follows:  
• Accidental overdose:  accidental administration of a drug in a quantity that i s higher than 
the assigned dose 
• Medicat ion error:  accidental deviation in the administration of a drug  
 In some cases, a medication error may be intercepted prior to administration of the drug.  Special situations are not in themselves AEs, but may result in AE s. Each AE associated with a 
special situation should be recorded separately on the AE eCRF. If the associated AE fulfills seriousness criteria, the event should be reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the event; see Section  8.4.2). For entrectinib , AEs  associated with 
special situation s should be recorded as described below for each situation:  
• Accidental overdose:  Enter the AE term. Check the “Accidental overdose” and 
“Medication error” boxes.  
• Medication error that does not qualify as an overdose:  Enter the AE term. Check the 
“Medication error” box. 
• Medication error that qualifies as an overdose:  Enter the AE term. Check the “Accide ntal 
overdose” and “Medication error” boxes.  
 
In addition, a ll special situations associated with entrectinib , regardless of whether they result in 
an AE, should be recorded on the AE eCRF and reported to the Sponsor immediately (i.e., no more than 24  hours after learning of the event). Special situations should be recorded as 
described below: 
• Accidental overdose:  Enter the drug name and “accidental overdose” as the event term. Check the “Accidental overdose” and “Medication error” boxes.  
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November 2018  Page 47 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 • Medication  error that does not qualify as an overdose:  Enter the name of the drug 
administered and a description of the error (e.g., wrong dose administered, wrong dosing 
schedule, incorrect route of administration, wrong drug, expired drug a dministered) as the 
event term.  Check the “Medication error” box. 
• Medication error that qualifies as an overdose:  Enter the drug name and “accidental 
overdose” as the event term.  Check the “Accidental overdose” and “Medication error” 
boxes. Enter a description of the error in the additional case details.  
• Intercepted medication error:  Enter the drug name and “intercepted medication error” as the event term. Check the “Medication error” box. Enter a description of the error in the 
additional case details.  
 As an example, an accidental overdose that resulted in a headache would require the completion of 2 AE  eCRF pages, one to report the accidental overdose and one to report the headache. The 
“Accidental overdose” and “Medication error” boxes would need to be checked on both eCRF pages.  
8.4.4 FOLLOW -UP OF SUBJECTS AFTER ADVERSE EVENTS  
8.4.4.1 INVESTIGATOR FOLLOW -UP 
The Investigator should follow each  AE until the event has resolved to baseline grade or better , 
the event is assessed as stable by the Investigator, the subject is lost to follow-up, or the subject 
withdraws consent. Every effort should be made to follow all SAEs considered to be related to study drug or trial-related procedures until a final outcome can be reported. During the study period, resolution of AEs (with dates) should be documented on the AE eCRF and in the subject’s medical record to facilitate source data verification.  
 All pregnancies reported during the study should be followed until pregnancy outcome. 
8.4.4.2 SPONSOR FOLLOW -UP 
For SAEs , AESIs, and pregnancies, the Sponsor or a designee may follow-up by telephone, fax, 
email, and/or a monitoring visit to obtain additional case details  and outcome information (e.g., 
from hospital discharge summaries, consultant reports, autopsy reports) in order to perform an 
independent medical a ssessment of the reported case. 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November 2018  Page 48 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 8.5 ADVERSE EVENTS  THAT OCCUR AFTER THE ADVERSE EVENT REPORTING 
PERIOD  
At the Follow -up/ET visit, the Investigator should instruct each subject to report to the 
Investigator any subsequent AEs that the subject’s personal physician believes could be related 
to prior study drug treatment or study procedures. The Sponsor should be notified if the Investigator becomes aware of any SAE that occurs after the end of the AE reporting period 
(defined as 28 days after the final dose of study drug) if the event is believed to be related to 
prior study drug treatment.  These events should be reported through the use of the AE eCRF. However, if the EDC system is not available, the Investigator should report these events directly to the Spon sor or its designee, 
by faxing or by scanning and emailing the paper Clinical Trial SAE/AE SI Reporting Form using 
the below fax number or email address provided to Investigators.  Genentech US Drug Safety Email Address:  us_drug.safety@gene.com  
Fax No.:  (650) 225-4682 
8.5.1 EXPEDITED REPORTING TO HEALTH AUTHORITIES, INVESTIGATORS, 
INSTITUTIONAL REVIEW BOARDS, AND ETHICS COMMITTEES  
The Sponsor will promptly evaluate all SAEs and AESIs against cumulative product experience to identify and expeditiously communicate possible new safety findings to Investigators, IRBs, ECs, and applicable health authorities based on applicable legislation.  To determine reporting requirements for single AE cases, th e Sponsor will assess the 
expecte dness of these events using the following reference document:  
 
• Entrectinib  IB 
 The Sponsor will compare the severity of each event and the cumulative event freq uency 
reported for the study with the severity and frequency reported in the applicable reference document.  Reporting requirem ents will also be based on the I nvestigator’s assessment of causality and 
seriousness, with allowance for upgrading by the Sponsor, as needed.  
 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November 2018  Page 49 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 The IRB will be notified by the investigative site in writing (e.g., email) within the timeframe 
required per local IRB regulations for when a reportable AE is first recognized or reported. In addition, a copy of the written confirmation or summary of the AE, as submitted to the Sponsor, will also be submitted to the IRB within that same timeframe from when the AE is first recognized or reported. The IRB Serious and Unexpected AE Submission Form will be completed and submitted with the copy of the written confirmation or summary of the AE. 
9 STATISTICAL ANALYSES  
The Safety Population will consist of all subjects who received at least 1 dose of study drug and 
have at least 1 postdose safety assessment.  
 
The PK Population will consist of all subjects who received at least 1 dose of study drug and 
have at least 1 evaluable postdose PK sample.  
 Baseline is defined as the last result prior to the first dose of study drug on Day 1 of Period 1. As 
necessary, baseline w ill be further defined in the Statistical Analysis Plan (SAP ). 
9.1 SAFETY AND TOLERABILITY ANALYSIS  
Safety will be assessed by a review of AEs, vital signs, clinical laboratory assessments, and 
ECGs. Clinical laboratory assessments, v ital signs (including oral  temperature, respiratory rate, 
and supine  blood pressure and pulse rate), and ECGs  will be listed by subject number and 
scheduled time.  Changes from baseline will be summarized , as appropriate. 
 Verbatim descriptions of AEs will be coded according to curr ent Medical Dictionary for 
Regulatory Activities version 21.1 (or higher) guidelines. Adverse events will be summarized. 
Enrollment and discontinuations from the study will be summarized overall. Demographics and baseline characteristics such as age, sex, and BMI will be summarized overall.  
9.2 PHARMACOKINETIC ANALYSIS  
The following PK parameters will be derived from the plasma  concentrations of entrectinib and 
M5 using the model independent approach:
5 
Cmax maximum observed concentration  
tmax time to maximum observed concentration 
AUC 0-t area under the concentration- time curve from Hour  0 to the last 
measurable concentration, calculated using the linear trapezoidal rule for increasing concentrations and the logarithmic rule for decreasing concentrations 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November 2018  Page 50 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 AUC 0-∞ area under the concentration-time curve extrapolated to infinity, 
calculated using the formula:  
AUC 0-∞ = AUC 0-t + 
zt
λC 
where C t is the last measurable concentration and λz is the apparent 
terminal elimination rate constant  
λz apparent terminal elimination rate constant, where λz is the 
magnitude of the slope of the linear regression of the log 
concentration versus time profile during the terminal phase 
t1/2 apparent terminal elimination half -life (whenever possible), where 
t1/2 = (ln2)/λ z 
CL/F  apparent systemic clearance, calculated as dose/AUC 0-∞ 
(entrectinib only)  
Vz/F apparent volume of distribution during the terminal elimination 
phase , calculated as (CL/F)/λ z (entrectinib only) 
 Pharmacokinetic calculations will be performed, if appropriate, using commercial software such as Phoenix WinNonlin (Certara Inc., version 6.4 or higher ). 
 Other parameters may be added , as appropriate. Final PK parameters reported will be detailed in 
the SAP . 
 Pharmacokinetic analysis will use actual times as recorded on the eCRF. Other data handling 
procedures will be detailed in the SAP. 
9.3 INTERIM ANALYSIS  
There will not be any interim analysis for this study.  
9.4 STATISTICAL ANALYSIS OF PHARMACOKINETIC DATA  
Descriptive statistics (mean, median, minimum, maximum, standard deviation, geometric mean, 
and geometric coefficient of variation  [CV]) will be calculated for all PK parameters and PK 
concentration data.  
 Plasma concentrations of entrectinib and its active metabolite M5, and derived plasma PK parameters, will be listed and summarized by treatment using descriptive statistics. Individual and mean concentration versus time profiles will be plotted.  
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November 2018  Page 51 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 The primary parameters for bioequivalence testing will be C max and AUC 0-t of entrectinib. A 
linear mixed model will be applied to analyze the log- transform ed primary PK parameters. The 
model assumes fixed effects for treatment, period, and sequence, and a random effect for subject 
within sequence . Estimates of geometric mean ratios on the original scale, together with the 
corresponding 90% CIs, will be derived for the comparisons between Test and Reference treatments. Bioequivalence will be concluded if the 90% CIs for the treatment ratios fall within the no-effect boundaries of 0.80 and 1.25.  
All calculations will be performed using SAS
 version 9.4 or grea ter. 
 
Specification of PK parameters for analysis; statistical level of significance to be used ; criteria 
for study termination; procedures for accounting for missing, unused, or spurious data ; 
procedures for reporting deviations from the original statisti cal plan ; and selection of subjects to 
be included in the analyses population(s) will be presented in the CSR and/or SAP , as 
appropriate. 
9.5 STATISTICAL ANALYSES OF SAFETY DATA  
Descriptive statistics will be calculated for the safety parameters. No formal statistical analyses 
are planned. 9.6 SAMPLE SIZE  
A total of 28 subjects will be enrolled to ensure that 26 subjects complete the study and have 
evaluable PK data from both treatment periods.  
In a previous study (Study RXDX-101- 15), the within- subject CVs for entrectinib AUC
0-∞ and 
Cmax following administration of a single dose of entrectinib were estimated to be 20% and 16%, 
respectively. Assuming a true ratio of 1.05 between the geometric means of Test and Reference 
treatments, and a within -subject CV of 21%, 26 evaluable subjects are needed to ensure there is 
at least 90% probability that the 90% confidence limits for the treatment ratios fall within the 
no-effect boundaries of 0.80 and 1.25 for each of the 2 primary PK parameters (AUC 0-∞ and 
Cmax). 
9.7 QUALITY CONTROL AND QUALITY ASSURANCE  
Quality control and quality assurance will be performed according to Covance Standard 
Operating P rocedures (SOPs) or per client request and as applicable according to the contract 
between Covance and the Sponsor. 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November 2018  Page 52 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 10 ADMINISTRATIVE ASPECTS  
10.1 CHANGE IN PROTOCOL 
There will be no alterations in the protocol without agreement between the Sponsor and the 
Investigator.  There will be no alterations in the protocol affecting subject safety without the express written approval of the Sponsor, Investigator , and the IRB (see F orm FDA 1572). 
10.2 INVESTIGATOR MEETING; SITE INITIATION 
Prior to the start of the clinical study, the representative(s) of the Sponsor will meet with the Investigator(s) and appropriate clinical staff to familiarize the Investigator and clinical staff with the materials necessary for conducting the clinical study. 
10.3 DISCLOSURE  
All information provided regarding the study, as well as all information collected  and 
documented during the course of the study, will be regarded as confidential. The Investigator 
agrees not to disclose such information in any way without prior written permission from the Sponsor.  Any publication of the results, either in part or in total (e.g., articles in journals or newspapers, oral presentations,  abstracts) by the Investigator(s) or their representative(s), shall require prior 
notification and r eview, within a reasonable timeframe, by the Sponsor, and cannot be made in 
violation of the Sponsor’s confidentiality restrictions or to the detriment of the Sponsor’s intellectual property rights.  
10.4 MONITORING (CLINICAL RESEARCH ASSOCIATE ) 
The Sponsor will designate a Sponsor’s Study Monitor who will be responsible for monitoring this clinical trial. The Sponsor’s Study Monitor will monitor the study conduct, proper e CRF and 
source documentation completion and retention, and accurate study drug accountability. To this end, the Sponsor’s Study Monitor will visit the study site at suitable intervals and be in frequent contact through verbal and written communication. It is essential that the Sponsor’s Study Monitor have access to all documents, including study data, subject medical records, and eCRFs, at any time these are requested. In turn, the Sponsor’s Study Monitor will adhere to all requirements for subject confidentiality as outlined in the ICF. The Investigator and Investigator ’s staff w ill be expected to cooperate with the Sponsor’s Study Monitor, to be 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November 2018  Page 53 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 available during a portion of the monitoring visit to answer questions, and to provide any missing 
information. 
10.5 INSTITUTIONAL REVIEW BOARD  
In accordance with 21 CFR 56, the protocol, advertisement, and ICF will be reviewed and 
approved by the IRB. The Sponsor will supply relevant material for the Investigator to submit to 
the IRB for the protocol’s review and approval. Verification of the IRB unconditional approval of the protocol and the written ICF statement will be transmitted to the Investigator.  The IRB will be informed by the Investigator of subsequent protocol amendments and of serious and unexpected AEs. Approval for protocol amendments will be transmitted in writing to the Investi gator . If requested, the Investigator will permit audits by the IRB and regulatory 
inspections by providing direct access to source data and documents.  The Investigator will provide the IRB with progress reports at appropriate intervals (not to 
exceed 1 year) and a Study Progress Report following the completion, termination, or 
discontinuation of the Investigator’s participation in the study.  
10.6 INFORMED CONSENT  
Written informed consent for the study will be obtained from all subjects before protocol- specific procedures are carried out. The ICF will be approved (along with the protocol) 
by the IRB and will be acceptable to the Sponsor.  The Investigator or designee will explain the nature of the study and the action of the test 
product. The subjects will be informed that participation is voluntary and that they can withdraw from the study at any time. In accordance with 21 CFR 50, the informed consent process shall be documented by the use of a written ICF approved by the IRB and signed by the subject prior to protocol-specific procedures being performed.  The subject will sign 2 copies of the ICF. One copy will be given to the subject, and the other 
will be maintained with the subject’s records.  
10.7 RECORDS  
The results from Screening and data collected during the s tudy will be recorded in the subject’s 
eCRF. To maintain confidentiality, the subjects will be identified only by numbers.  
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November 2018  Page 54 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 The completed eCRFs will be transferred to the Sponsor or designee. Copies of each e CRF will 
be retained by the Investigator. All source documents, records, and reports will be retained by the 
study site in accordance with 21 CFR 312.62(c).  All primary data, or copies thereof (e.g., laboratory records, e CRFs, data sheets, correspondence, 
photographs, and computer records), which are a result of the original observations and activities 
of the study and are necessary for the reconstruction and evaluation of any study report, will be retained in the study site archives.  
10.7.1 ELECTRONIC CASE REPORT FORMS  
Electronic Case Report Form s are to be completed using the Medidata RAVE EDC system. The 
site will receive training and have access to a manual for appropriate eCRF completion. 
Electronic Case Report Forms will be submitted electronically to Covance and should be handled 
in accordan ce with instructions from Genentech/Covance. All eCRFs should be completed by 
designated, trained examining personnel as appropriate.  The results from Screening and data collected during the study will be recorded in the subject’s 
eCRF. To maintain confidentiality, the subjects  will be identified only by numbers. The 
Investigator will ensure the accuracy, completeness, legibility, and timeliness of the data reported in the eCRF by providing an electronic signature. The completed eCRFs will be transferred t o the Sponsor or designee. 
 In addition, at the end of the study, the Investigator will receive subject data for the site in a readable format (e.g., a compact disc) that must be kept with the study records. 
10.7.2 SOURCE DATA DOCUMENTATION  
Study M onitors will pe rform ongoing source data verification  and review to confirm that critical 
protocol data (i.e., source data) entered into the eCRFs by authorized site personnel are accurate, 
complete, and verifiable from source documents.  
 Source documents (paper or elect ronic) are those in which subject data are recorded and 
documented for the first time. They include, but are not limited to, hospital records, clinical and office charts, laboratory notes, memoranda, subject diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copies of transcriptions that are certified after verification as being accurate and complete, microfiche, photographic negatives, microfilm or magnetic media, X -rays, subject files, and records kept at the pharmacy, 
laboratories, and medico- technical departments involved in a clinical trial. Source documents 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November 2018  Page 55 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 that are required to verify the validity and completeness of data entered into the eCRFs must 
never be obliterated or destroyed. To facilitate source data verification  and review , the 
Investigator and institution(s) must provide the Sponsor direct access to applicable source documents and reports for trial-related monitoring, Sponsor audits, and IRB/ EC review. The 
study site must also allow inspection by applicable health authorities.  
10.7.3 USE OF COMPUTERIZED SYSTEMS  
When clinical observations are entered directly into a study site’s computerized medical record system (i.e., in lieu of original hardcopy records), the electronic record can serve as the source document if the system has been validated in accordance with FDA requirements pertaining to computerized systems used in clinical research. An acceptable computerized data collection system (for clinical research purposes) would be one that (1) allow s data entry only by 
authorized individuals; (2) prevents the deletion or alteration of previously entered data and provides an audit trail for such data changes (e.g., modification of file); ( 3) protects the database 
from tampering; and (4) ensures data preservation.  
 In collaboration with the Study Monitor, Genentech’s or Covance’s Quality Assurance group may assist in assessing whether electronic records generated from computerized medical record systems used at study sites can serve as source documents for the purposes of this protocol. If a 
site’s computerized medical record system is not adequately validated for the purposes of clinical research (as opposed to general clinical practice), applicable hardcopy source documents must be maintained to ensure that critical protocol data entered into the eCRFs can be verified.  
10.7.4 STUDY MEDICATION ACCOUNTABILITY 
The recipient of study medication will acknowledge receipt by returning the appropriate documentation form indicating shipment content and condition. Damaged supplies will be replaced. Accurate records of all study drug received at, dispensed from, returned to, and disposed of by the study site should be recorded by using the Drug Inventory Log.  Study drug will either be disposed of at the study site according to the study site’s institutional SOP or returned to Genentech with the appropriate documentation, as determined by the 
Sponsor. If the study site is able to destroy study drug, the method of destruction must be documented. Genentech must evaluate and approve the study site’s drug destruction SOP  prior to 
the initiation of drug destruction by the study site. 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November 2018  Page 56 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 10.7.5 DISCLOSURE OF DATA  
Subject medical information obtained by this study is confidential and may only be disclosed to 
third parties as permitted by the ICF (or separate authorization to use and disclose personal health information) signed by the subject or unless permitted or required by law. Medical information may be given to a subject’s personal physician or other appropriate medical personnel responsible for the subject’s welfare for treat ment purposes. 
 Given the complexity and exploratory nature of the analyses, data derived from exploratory biomarker specimens will generally not be provided to study Investigators or subjects unless required by law. The aggregate results of any conducted research will be available in accordance with the effective Sponsor policy on study data publication.  Data generated by this study must be available for inspection upon request by representatives of the US FDA and other regulatory agencies, national and l ocal health authorities, Genentech 
monitors/representatives and collaborators, and the IRB/ EC for the study site, if appropriate.  
 Study data may be submitted to government or other health research databases or shared with researchers, government agencies,  companies, or other groups that are not participating in this 
study. These data may be combined with or linked to other data and used for research purposes; to advance science and public health ; or for analysis, development, and commercialization of 
products to treat and diagnose disease. In addition, redacted CSRs and other summary reports 
will be provided upon request. 
10.7.6 RETENTION OF RECORDS  
The US FDA regulations (21 CFR §312.62[c]) and the ICH Guideline for GCP require that 
records and documents pertaining to the conduct of this study and the distribution of 
investigational drug, including eCRFs, ICFs , laboratory test results, and medication inventory 
records, must be retained by the Investigator for 2 years after the last marketing application approval in an ICH region or after at least 2 years have elapsed since formal discontinuation of clinical development of the study drug. All state and loc al laws for retention of records also 
apply. No records should be disposed of without the written approval of the Sponsor . Written 
notification should be provided to the Sponsor prior to transfer ring any records to another party 
or moving them to another location. For studies conducted outside the US under a US Investigational New Drug ( IND), the Investigator must comply with the record retention 
requirements set forth in the US FDA IND regulations and the relevant national and local health 
authorities, whichever is longer.  
 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November 2018  Page 57 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 All primary data, or copies thereof (e.g., laboratory records, eCRFs, data sheets, correspondence, 
photographs, and computer records), which are a result of the original observations and activities of the study and are necessary for the reconstruction and evaluation of any study report will be 
retained in the study site archives.  
10.8 REFERENCE TO DECLARATION OF HELSINKI/BASIC PRINCIPLES  
The study procedures outlined in this protocol will be conducted in accordance with the US CFR governing Protection of Human Subjects (21 CFR 50), Financial Disclosure by Clinical Investigators (21 CFR 54), IRBs  (21 CFR 56), IND Application (21 CFR 312), and Applications 
for FDA Approval to Market a New Drug (21 CFR 314), as appropriate. As such, these sections of US Title 21 CFR, along with the applicable ICH Guidelines, are commonly known as GCP, which are consistent with the Declaration of Helsinki.  
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November 2018  Page 60 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 REFERENCES  
1. Weinstein IB and Joe AK. Mechanisms of disease:  Oncogene addiction--a rationale for 
molecular targeting in cancer therapy. Nat Clin Pract Oncol 2006;3:448- 57. 
2. Weinstein IB and Joe AK. Oncogene a ddiction. Cancer Res 2008;68:3077-80. 
3. Entrectinib (RXDX -101). Investigator’s Brochure. Ignyta, Inc. Edition 008. Apr2018. 
4. RXDX-101-15:  A 2 -Part, Open-Label, Randomized, 2-Period, Single-Dose, Study to 
Assess the Relative Bioavailab ility of 2 Entrectinib F ormulations Under Fasting 
Conditions and the Effect of Food on the Entrectinib F06 Formulation in Healthy Adult 
Male Subjects.  
5. Gibaldi M, Perrier D. Pharmacokinetics. 2 nd ed. New York, NY:  Marcel Dekker, Inc. , 
1982. 
 
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November 2018  Page 61 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 APPENDIX A – CLINICAL LABORATORY EVALUATIONS  
Chemistry  Panel  (Fasted  at least 
8 hours ): Complete Blood Count:  Urinalysis:  
Alanine aminotransferase  
Albumin  
Alkaline phosphatase  
Aspartate aminotransferase  
Blood urea nitrogen  
Calcium  
Chloride  
Cholesterol  
Creatinine  
Creatine kinase /Creatine phosphokinase  
Glucose  
Potassium  
Sodium  
Total bilirubin  
Total protein  
Triglycerides  
Uric acid 
 Hematocrit  
Hemoglobin  
Mean corpuscular hemoglobin  
Mean corpuscular hemoglobin 
concentration  
Mean corpuscular volume  
Platelet count  
Red blood cell (RBC) count  
RBC distribution width  
White blood cell (WBC) count  
WBC differential (absolute):  
Basophils  
Eosinophils  
Lymphocytes  
Monocytes  
Neutrophils  Bilirubin  
Color and appearance  
Glucose  
Ketones  
Leukocyte esterase  
Nitrite  
Occult blood  
pH and specific gravity  
Protein  
Urob ilinogen 
Microscopic exam including 
bacteria, casts, crystals, epithelial cells, RBCs, and WBCs (if 
protein, leukocyte esterase, nitrite, 
or blood is positive)  
Drug Screen:  Other Tests:  
Including but not limited to the 
following:  
Alcohol (ethanol)a 
Amphetamines Barbiturates  
Benzodiazepines  
Cannabinoids (THC)  
Cocaine (metabolite)  
Methadone  
Opiates  
Phencyclidine  
Cotinine
b Hepatitis B virus core antibodyb 
Hepatitis B surface antigenb 
Hepatitis C virus antibodyb 
Human i mmunodeficiency virus antibodyb 
Pregnancy test (females of childbearing potential only; serum qualitative)  
Follicle -stimulating hormone (postmenopausal females only)b 
 
a Alcohol breath testing will be performed at Check -in (Day -1) only.  
b Measured at the Screening visit only. 
  
Clinical Protocol  
Covance Study 8397015 CONFIDENTIAL  
Protocol GP41049 
 
 
Final :  5 November 2018  Page 62 of 62 
CPET Protocol Template, Version 11.0:  30 April 2018 APPEN DIX B – APPROXIMATE MAXIMUM BLOOD VOLUME COLLECTED  
Note:  Additional samples may be drawn for safety purposes. 
 
 Sample Volume  
(mL)  Number of 
Samples  Total Volume  
(mL)  
Serology  7.0 1 7.0 
Chemistry Panel (includes serum pregnancy and 
FSH)  8.5 5 42.5 
CBC (hematology ) 4.0 5 20.0 
PK Samples  4.0 30 120 
Total  189.5 
CBC = complete blood count; FSH = follicle -stimulating hormone; PK = pharmacokinetic.  
 